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Abstract
Combination of nanoparticles (NPs) and pharmaceutically active compounds like drug
molecules are very effective in drug delivery systems due to their superior performance
and selectivity. These advanced nanostructured drug carriers are also employed to de-
liver nucleic acids and proteins to the diseased site. Drug targeting and release to the
infected site have now become popular both in in vitro and in vivo research areas.
Multifunctional NPs used in drug delivery applications offers several advantages such
as increase stability of NPs, modify optical, magnetic, electronic properties as well as
incorporate biocompatibility and stimuli responsive behavior within a single framework.
Several studies have been done with inorganic NPs and polymeric NPs and combination
of these, for example conjugation of thermoresponsive polymers with gold nanoparticles
(Aunps) were studied and properties of these constructs were compared with the free
polymer drug carrier system.
System used in this work is comparatively unique and different in the sense that Fe@Au
NPs conjugated with hydrogels have not studied prior to this study. In this research,
inorganic (Fe@Au) and polymeric NPs (pNIPAm/AAc and PEG) are gelled together,
to from a multifunctional drug carrier. Most important attribute which these nano-
constructs should have is stability and effective release kinetics of the loaded drug. The
master thesis has focused primarily on the loading and release of drug and protein
molecules. First, Fe@Au were synthesized from previously established method at Ugel-
stad laboratory, NTNU. These NPs were then characterized using DLS (Dynamic Light
Scattering), zeta-size, UV-vis (Ultra-violet spectroscopy) and S(T)EM. In order to in-
vestigate the variations of the sizes and zeta potentials as a function of temperature and
pH (in case of size) as well as structural framework and UV-vis spectra of formed NPs
respectively. Thereafter these NPs were coated with pNIMPm/AAc hydrogels (which
were optimized previously at Ugelstad laboratory, NTNU), PEG and the combination of
these polymers. Coated sample were also characterized with the same techniques as used
for Fe@Au NPs. Loading studies were performer with three drugs L-dopa, coumarin and
cytochrome c and estimated with UV-vis using calibration curves for the drugs. Drug
loading was optimized and concentration of drug and NP which gives maximum loading
efficiency was used for the release studies. Release of the loaded drugs were observed
at high temperature (40oC) and low pH (3.5). Drug release was also measured with
UV-vis.
i
Two methods were used for coating of Fe@Au NPs, method 1 and method 2. Method
2 provides better loading efficiencies compared to method 1 and therefore used in this
study. Size of pNIMAm/AAc based hydrogels decreased at higher temperature due
to transition from hydrophilic to a hydrophobic state. VPPT for heating and cooling
shown by hydrogels alone is 38oC, which indicated their reversibility. Size increased for
Fe@Au NPs coated with the hydrogel probably due to the cross-linking effect provided
by Fe@Au NPs. VPTT is observed when for heating and cooling is calculated as 39.8oC
and 39.5oC for coated samples. Fe@Au PEG Hydrogel system shows appreciable re-
versibility with VPPT values for heating and cooling reported as 37.1 oC and 36.7 oC. pH
Effect on size is similar to temperature effect. Cytochrome C loading shows high loading
efficiencies of 31.66 % and 32.57 % for Fe@Au Hydrogel and Fe@Au PEG Hydrogel re-
spectively. Highest release of 87.20 % was obtained from Fe@Au Hydrogel system, while
Fe@Au PEG Hydrogel system shows fastest release rate. In case of Cytochrome C, both
highest and fastest release were given by Fe@Au PEG. However, Fe@Au PEG Hydrogel
system also shows almost identical t1/2 in comparison to Fe@Au PEG.
Polymer-NPs hybrids shows promising loading and release of the drugs with change
in temperature and pH. Which highlight their superiority as a drug carrier compared
to only polymeric and inorganic system. Further studies with these systems can be
developed in which two drugs at the same time can be loaded and released from this
nanocarrier system.
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Chapter 1
Introduction
1.1 Nanoparticles
Nanoparticles (NPs) can be defined in terms of diameter as the particles which have di-
mensions in the range from 1 to 100 nanometers [1]. NPs have gained immense attention
of researchers in recent years due to their size dependent properties.
Nanotechnology is the science that addresses the process which occurs at molecular and
atomic levels. It concerns with the design, synthesis and characterization of nanos-
tructures by regulating the size and shape at nano scale. Nanomaterials have a high
surface area to volume ratio which finds applications in different fields like catalysis,
drug delivery, imaging and so on. Magnetic, thermal and electrical properties of these
nanomaterials also vary from the bulk properties due to transition to the nano regime.
For example, the melting point of gold changes from 200 oC to 1068 oC at nanoscale [2].
Latest therapeutic and diagnostic concepts in the medicine field are mostly based on
nanotechnology because of better performance [3]. NPs are getting great attraction
particularly in the field of drug delivery, due to their unique properties and very few
side effects [4]. It is expected that the global market for drug delivery will rise from US$
131.6 billion in 2010 to US$ 175.6 billion by 2016, that is rise in the market value at
a compound annual growth rate of 5 %. Furthermore, this increase will be continuous
and the market value will reach a value of US$ 225.8 billion by 2020 [5] as illustrated in
Figure 1.1 a) and b).
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Figure 1.1: a) Worldwide Drug Delivery Market 2010-2014 b) Worldwide Drug De-
livery Market 2014-2020 [5]
Currently, there are around 30 drug delivery products in the market for cancer treatment,
with a total annual income of about US 33 billion. About 15 % increase in growth is
expected on an annual basis. In 2011, the global market for NPs in drug development
and drug delivery was worth around 17.5 billion and it is expected to rise to 53.5 billion
in 2017. Moreover, in 2021 it is expected that the market value will increase to 136
billion (cancer treatment) [6]. Figure 1.2 shows the global market trend nanotechnology
in drug delivery for cancer treatment.
Figure 1.2: Global Market trend for Nanotechnology in Drug Delivery for cancer
treatment [6]
Several processes are used for nanomaterials fabrication. Synthesis methods vary be-
cause of a number of factors like approach used (top-down/bottom-up), phase of syn-
thesis (gaseous/aqueous phase), type of nucleation (heterogeneous/homogeneous), media
used for synthesis (bulk/emulsion), and type of core/shell (magnetic or other), type of
material (organic/inorganic). In this chapter, different types of NPs, both inorganic and
polymeric, will be first discussed in terms of their synthesis and properties. Then, the
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suitability of such with respect to drug delivery applications will be discussed. There-
after, a detailed insight would be given into various modes of drug delivery. Finally, an
overview of release kinetics models will be given.
1.2 Inorganic NPs
Depending on the end use, inorganic NPs can be synthesized using different methods.
Further, the choice of method depends on intended particle size, shape, distribution,
surface functionality and so on [7]. Among various kinds of inorganic NPs, metallic
core-shell NPs have gained immense attention in the recent years, owing to their multi-
functional properties, stemming from different counterparts.
1.2.1 Synthesis Methods for Core-Shell NPs
Synthesis of core-shell NPs is a two-step process, in the first step, core is formed, while
in the second step, shell formation takes place. Two routes (i) pre synthesized and (ii)
in-situ synthesis are normally employed depending on the availability of core. In pre
synthesized process, core and shell synthesis take place separately. First, core particles
are produced and afterwards, clean and dried particles are put in a separate reaction
mixture to produce the shell. However, in case of in-situ production method, reactants
used for shell formation are added to the already synthesized core [8]. Both routes
face problems of agglomeration of particles, incomplete coverage of the core, and poor
control over the reaction rate [9]. Some of the synthesis methods which are widely used
to produce such NPs are discussed in the following sub-sections.
1.2.1.1 Solution Based Synthesis
Solution based synthesis of NPs is generally based on the reduction of metal complexes
in dilute solution. Different methods have been established to start and control the
reduction reactions [10]. The sequence for the formation of NPs by this method is
shown in Figure 1.3.
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Figure 1.3: Sequence for the formation of NPs in solution based synthesis [11]
Aqueous medium, use of surfactants and reducing agents all are important and play
major roles in the preparation of metallic NPs. Different kinds of metal precursors,
reducing agents and stabilizing agents are used, also the strength of the reducing agent
plays critical role in controlling the reaction rate and particle size [8].
Metal precursors used are combinations of elemental metals, inorganic salts and metal
complexes, for example, Ni, Ag, Co, Fe, Ni, HAuCl4, H2PtCl6, RhCl3 and PdCl2 [10].
Mostly used reducing agents are sodium borohydride [12], hydrazine, sodium citrate,
hydrochloride (salt formed by reaction of hydrochloric acid with base) , citric acid, car-
bon monoxide, sodium carbonate and sodium hydroxide [10]. Stabilizers like polyvinyl
ether, polyvinyl alcohol and sodium polyacrylate are used to stabilize formed NPs [13].
Reducing agent has a significant effect on the size and size distribution of the NPs. Small
NPs are generally formed by strong reduction reaction as they promote fast reaction rates
[10]. Narrow or wider size distribution of particles can be achieved with slow reaction
rates depending on the formation of new nuclei or secondary nuclei. The strength and
concentration of the reducing agent dictates the supersaturation. Higher supersaturation
leads to the formation of a large number of nuclei, and hence small sized NPs [10].
NPs are stabilized with different polymers that provide steric stabilization and prevent
agglomeration of the NPs. Interaction of polymer stabilizers with the surface of solid
particles is highly dependent on the type of polymer, solvent, surface chemistry of NP
and temperature. Stabilizing agents also provide functionalization of NPs like polarity
change, solubilisation and capacity to encapsulate new molecules. NPs can be function-
alized with more than one type of ligand, these are called multifunctional nanoparticles.
Multifunctional nanoparticles are very popular in drug delivery systems [10].
4
Chapter 1. Introduction 1.2 Inorganic NPs
1.2.1.2 Electrotemplating
In this method, electrolysis process is utilized in which anode is made of (required)
metal and cathode is inert. Solution of stabilizer is electrolysed. Oxidation of anode
material causes its dissolution under specific conditions of electrolysis. Movement of
cations towards cathode causes the reduction, nucleation and stabilization. Current
density can be used to change the size of the NPs prepared by this method. Formation
of bi metallic nanoparticles can occur by employing pair of anodes of different metals.
Sometimes it is difficult to cause the oxidation of anode metal, this problem can be
solved by introducing metal as an inorganic salt [11].
Electrochemical process is also used to produce NPs from polymers and dispersions of
NPs in aqueous medium. In a relatively new method, deposition of NPs (which were
first added in aqueous phase) is done on conductive polymer using required electric field
[11].
Electrochemical synthesis of NPs has become important especially in the preparation of
composites of metal particles and conducting polymers as core-shell constructs. NPs in
polymer matrix increase the mass transfer parameters of the nano-composites because
electron tunnelling distance is shortened. Properties like this make polymer/stabilized
metallic NPs an important class of materials [11].
1.2.1.3 Sol-gel
Sol-gel is an extensively used process for the preparation of metal oxide NPs; it is a
wet chemical method. This process involves hydrolysis and polycondensation of precur-
sors like metal alkoxides or chlorides, leading to the formation of solid-phase network
(dispersion of oxide particles in a solution) [8][14].
Solvent removal or chemical reaction is used to dry or gel the sol. Precursors can be
hydrolyzed with an acid or base but in most cases, water is used. There are three
different routes into which sol gel process can be divided (i) gelation of colloidal powder
solutions (ii) hydrolysis and polycondensation of metal salt precursors succeeded by
aging and drying under ambient conditions and (iii) hydrolysis and polycondensation of
metal precursor succeeded by hypercritical drying of the gels [15].
To form a sol or colloidal suspension, the precursor goes through a series of polymer-
ization and hydrolysis reactions. Hydrolysis and condensation rates can change the
properties of end product, for example, slow and controlled hydrolysis rates give small
particles[16][17]. Temperature and pH also affect the particle size. Iron oxide supported
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on silica gel[17] and magnetite [18] have been prepared very often by this method.
Schematic representation of sol-gel process is shown in Figure 1.4.
Figure 1.4: Schematic representation of sol-gel process [19]
1.2.1.4 Micro-emulsion based synthesis
In this method, two immiscible liquids are dispersed to form a thermodynamically sta-
ble, isotropic system. Interfacial film of surfactant molecules is used to stabilize the
micro domain of two liquids [20]. Water phase is dispersed as micro-droplets having
1-50 nm diameter. A monolayer of surfactant molecules in the hydrocarbon phase sur-
rounds these micro-droplets. Molar ratio of water to surfactant is used to estimate the
size of the reverse micelles and hence the size of the NPs [21]. Water in oil micro emul-
sions, one having the reducing agent while the other having the metal precursor, are
mixed, resulting in continuous collisions. This leads to coalescence of the micro-droplets
leading to reaction and formation of NPs [22]. The NPs are separated from the excess
surfactants by adding solvents like acetone or ethanol followed by centrifugation steps.
Thus, microemulsions are used as nano-reactors for the synthesis of NPs as their sizes
limit the growth of the NPs [23]. Figure 1.5 depicts the steps involved in the synthesis
of NPs by micro-emulsion based synthetic route.
This method has been widely used to produce metallic cobalt, cobalt/platinum alloys
and cobalt/platinum NPs coated with gold in reverse micelles of cetytrimethlyammonium
bromide, using 1-butanol as cosurfactant and octane as the oil phase [25].
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Figure 1.5: Steps involved in the synthesis of NPs by micro-emulsion based synthetic
route [24]
1.2.2 Magneto-plasmonic NPs
Recently, innovative multifunctional NPs have gained great consideration, because they
have the capability to import distinct functionalities to attain collegial therapeutic treat-
ment. Multifunctional NPs are fabricated to co-transport multiple cargo molecules, and
at the same time, they assist in the delivery of drug through NP surface-cell interactions,
serving both in therapy and diagnosis[26]. Combining material properties of constituting
metals in core-shell NPs is one such example.
1.2.2.1 Magnetic NPs and Superparamagnetism
Magnetic NPs are playing a critical role in the broad spectrum of bio-medical appli-
cations, such as biomedical sensing, targeted drug delivery, and ultra-sensitive disease
detection. Due to small particle size, there is an enhancement in reactivity and they have
strong magnetic properties because of superparamagnetism and surface effects. Further,
they can reach the site of concern more precisely owing to their size and functional-
ization. These particles can be coated with biological molecules, thereby promoting
interactions with biological systems[26][23].
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As mentioned above, magnetic NPs have strong magnetic properties due to superpara-
magnetism, so it is important here to give a brief overview of superparamagnetism.
In paramagnetic phase, material shows randomly oriented magnetic dipoles that arrange
in a straight line and along its direction under the influence of external magnetic field.
When magnetic field is removed, high thermal energy decouples all the spins. While
in case of superparamagnetism, material shows magnetic effect in which all the spins
are always collinear to each other but anisotropic energy is not high enough to keep
them aligned along stable magnetocrystalline direction. As a result, superparamagnetic
material displays constant and collective fluctuations of its spins. This means that these
dipoles move collectively in a random way and are always aligned parallel to one an-
other. Spins align in the same direction only when external magnetic field is applied
in a certain direction. Superparamagnetic response of the material is dependent on the
relaxation time and measuring time of the technique [27]. The main difference between
superparamagnetic and paramagnetic material is that the transition for superparamag-
netic material happens below the Curie temperature. Figure 1.6 shows the difference
between superparamagnetic and ferromagnetic particles.
Figure 1.6: Superparamagnetic versus ferromagnetic particles in (a) the absence and
(b) the presence of an external magnetic field [28]
Coating of magnetic NPs with noble metals like gold is done to utilize the optical prop-
erties of the gold NPs.
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1.2.2.2 Coating of magnetic NPs and localized surface plasmon resonance
(LSPR)
Coating of magnetic nanoparticles (MNPs) with biocompatible materials like silica and
gold is gaining importance in the development of MRI contrast agents for drug delivery.
Coating with precious metals offers several advantages. For instance, gold has low reac-
tivity and it is considered an inert coating. A gold layer prevents chemical degradation
of magnetic cores and also forbids release of potentially toxic components. Adding gold
offers additional advantage of forming self assembled monolayers (SAMs) on the surface
of MNPs using alkanethiols. Gold coating also improves the ability of NPs to attach
with functional ligands and functional chemistries are improved drastically as compared
to MNPs[29].
As mentioned above, chemical inertness of gold offers several advantages, but on the
other hand, this chemical inertness is disadvantageous in a sense that it is difficult to
form gold shells over MNPs. Advanced methods offer a way to form gold-coated iron
NPs. These methods include reverse microemulsions, combined wet chemical methods
and laser irradiation [29].
One of the most exploited properties of gold NPs is LSPR. Conduction band electrons
on the surface of noble metal NPs undergo polarization when they absorb light. This
polarization is triggered by the electromagnetic field of the incident light. Polarized
electrons go through collective oscillations due to positive ions in the metallic lattice.
These oscillations are called surface plasmon oscillations. Surface plasmon oscillations
have the same frequency as the incident light that is why this phenomena is also called
surface plasmon resonance and in case of NPs, these surface plasmons are confined and
the phenomenon is thus known as LSPR. Intensity and position of LSPR is affected
by the shape, size and material of the NPs. For spherical gold NPs, the wavelength at
which LSPR happens is around 520 nm which falls in the visible region [30]. Figure 1.7
illustrates how LSPR occurs in noble metals.
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Figure 1.7: Light causes the electrons of the NPs to delocalize forming an electric
field opposite to that of the wave [31]
MNPs can also be coated with different kinds of polymers to introduce multifunctionality,
1.2.2.3 Polymer coating of MNPs
MNPs utilize their high surface energy to agglomerate. Salts or electrolytes which are
present in biological solutions can neutralize the charges present on the surfaces of NPs.
This neutralization can cause agglomeration of the NPs. In addition to this, surfaces of
MNPs are subjected to opsonisation -the first step during their clearance by reticuloen-
dothelial system (RES) when they are injected into the body. To effectively escape the
uptake by the RES and maintain longer plasma half-life, as well as to prevent agglom-
eration, it is important to coat the surface of MNPs. Some common coating schemes
of MNPs are represented in Figure 1.8 [29]. Surface properties like surface charge and
chemical functionality are also modified with these coatings. Few important parameters
which should be kept in mind with respect to polymeric coating of MNP systems are
types of chemical structure of the polymer (hydrophobic/hydrophilic, biodegradation),
molecular weight of the polymer, conformation of polymer, degree of particle surface
coverage and the manner in which polymer is attached. These factors can affect the
performance of MNP systems .Polymers can be attached to the surface of particles in
a number of different arrangements, for example, in the form of end-grafted brushes,
or as completely encapsulated polymers shells. These different orientations along with
molecular weight can affect antifouling characteristics of NPs and their hydrodynamic
sizes [29].
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Figure 1.8: Magnetic nanoparticles coating schemes: (A) Coated with End-grafted
(B) Encapsulated in polymer coating (C) Liposome encapsulated (D) Core-Shell (E)
Heterodimer [29]
1.3 Polymeric NPs
On the other hand, polymeric NPs have shown superior characteristics as a medium for
delivery of drugs, biomolecules and genes. These polymeric NPs are generally known
as polymeric colloidal particles because their size range falls within the colloidal regime
[32, 33]. Biocompatibility, low toxicity and biodegradability of polymeric NPs are their
prominent features which are utlized in drug delivery strategies. In addition, these poly-
meric NPs can be easily functionalized to produce multifunctional vectors for advanced
drug delivery applications. It is important to mention that size, shape and surface prop-
erties of the NPs can be customized, along with degradation kinetics and mechanical
properties [34].
Polymeric NPs have the ability to entrap and adsorb both hydrophilic and hydrophobic
molecules with ease and provide intended results. These NPs are also very stable [35].
Molecules like proteins, peptides are protected from degradation because of drug entrap-
ment with polymeric NPs. Apart from this attribute, they also facilitate controlled drug
release and site-specific drug targeting [36]. Furthermore, nano scale polymeric NPs are
able to cross extra and intercellular barriers. These systems can cross endothelium and
deliver the entrapped drug to the tumor site [36, 37].
Normally, two types of polymeric NPs are widely considered in regards to drug delivery
- nanospheres and nanocapsules. In nanospheres, drug molecules are dispersed homoge-
neously in the polymer matrix. On the other hand, nanocapsules are typical vesicular
systems constructed of polymers in which the polymer wall surrounds a core where the
drug molecule is entrapped [36]. A number of different processes are developed to syn-
thesize polymeric NPs. Most common of these processes are spray-drying, salting out,
nano-precipitation and emulsion-based methods [38]. Size and surface of the produced
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NPs will be dependent on the method employed for their production and the given pro-
cess can dictate the properties and features of NPs. In addition to that, in order to get
the required characteristics of the formulation, it is important to have a good under-
standing of the different experimental variables [38, 39]. In the following sub-sections, a
brief overview of different kinds of polymeric NPs is being presented.
1.3.1 Polymeric Micelles
Polymeric micelles are termed as self-assembled particles that have gained popularity as
spherical nano-scale carriers for delivery of drugs, proteins, genes and imaging agents
[40]. These structures are constructed by self-assembly of amphiphilic block or graft
copolymers in aqueous solution. Size of polymeric micelles is in the range of 10 to 100
nm with hydrophobic a core and a hydrophilic surface [41, 42]. The core-shell structure
comprises a shell of hydrophilic polymer chains which surrounds the inner hydrophobic
core. Hydrophobic or water insoluble drugs are delivered by using polymeric micelles
because they can be encapsulated in the hydrophobic core of the micelles. Figure 1.9
shows the hydrophilic shell in these structures that prevents the deterioration of the
micelles in the aqueous dispersion [41–43].
These systems can increase the bio-availability of the drug as they prevent the physically
entrapped drug from hydrolysis and enzymatic degradation which ultimately prolong the
blood circulation times of the micelles [40, 44]. Low toxicity is also a positive attribute
of these systems [44].
Figure 1.9: Micelle structure [43]
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1.3.2 Dendrimers
Dendrimers are synthesized by convergent or divergent polymerization of branching
units. This results in structures made of a hydrophilic surface and a hydrophobic cen-
tral core as shown in Figure 1.10 [45]. Dendrimers can be produced from a branching
monomer, central core and functionalized peripheral groups and they are generally called
hyperbranched nanocarriers. In the case of divergent polymerization, formation starts
from the core element, while in convergent polymerization growth starts from the pe-
ripheral branching units [45].
Low viscosity, hyperbranched molecular structure, macromolecular size and multiple end
groups which can be functionalized are key physico-chemical properties of the dendrimers
[45]. Wong et al. (2012) [46] describes the controlled release of loaded cargo from these
systems by altering the de-polymerization of dendrimers.
Figure 1.10: Formation of dendrimers by convergent and divergent polymerization
[45]
Drug molecules can be delivered to specific sites by using dendrimers either by incorpo-
rating it in the core and branches, or by conjugation to terminal groups [45]. Dendrimers
also find their application as diagnostic tools because of their capablity to protect imag-
ing agents, reducing their toxicity and also upgrading the specificity of imaging agents
[47].
1.3.3 Hydrogels
Hydrogels comprise hydrophillic organic polymer components that are cross-linked into
a network by either covalent or non/covalent interactions [48, 49]. They show swelling-
collapse behavior in aqueous media upon water ingestion or as a function of temperature
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and/or pH. In these structures, large solvent contents induce fluid-like properties while
cross-linking provides the dimensional stability. Many research groups are now focussing
on fabrication of more complex polymer constructs (hydrogel based) to obtain highly
functional nanomaterials. This interest is developed to create impact in the fields like
in-vivo diagnostics, drug/gene delivery and optical materials [50]. These materials are
intended for biocompatibility, biodegradation, encapsulation, biorecoginition, environ-
mentally switchable payload release and/or directed self-assembly. Utilization of stimuli-
sensitive polymers in nanostructured hydrogels enables them to sense and respond to
the local conditions. For instance, it is conceivable to envision the formation of a hy-
drogel molecule that embodies and protects a pharmacologically dynamic protein, just
releasing it when the molecule “detects” the vicinity of a specific infection state [50].
Hydrogels can be classified from numerous points of view, yet discussion here will be
limited to only classification based on the type of cross-links. Important attributes of
the cross links is the maintenance of a network structure of the hydrogels and to avoid
the disintegration of the hydrophilic chains [50].
1.3.3.1 Physically Cross-linked Hydrogels
Hydrogels (both synthetic and natural) in this class have prompted the idea of reversible
or degradable polymers that experience a shift from a three-dimensionally stable struc-
ture to a polymer solution. These hydrogels have been frequently utilized to embody
proteins [51], cells, or drugs [52] and afterwards release them by dissolution of the hy-
drogel structures. Hydrophobic interactions, hydrogen bonding, or ionic interactions fall
under the non-covalent attractive forces between the polymer chains and are responsible
for the cross-linking in physically cross-linked hydrogels [50].
1.3.3.2 Chemically Cross-linked Hydrogels
Chemically cross-linked hydrogels are normally more stable than the physically cross-
linked hydrogels on the grounds that they are formed by covalent bonds [53]. Hydrogels
formed by such cross-links have a perpetual structure unless chemical liable bonds have
been deliberately added to the system to make the hydrogels degradable. Monomers are
polymerized in the presence of the cross-linking moieties to form chemically cross linked
gels. Different physical properties, for example, the swelling limit of hydrogels can be
controlled by controlling the amount of cross-linker utilized [53].
Hydrogels can likewise be categorized taking into account their size as either macro-
gels [54, 55] or microgels [56, 57]. Size can vary from millimeters and bigger in case
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of macrogels and they are termed as bulk gels, while microgels are colloidally stable
hydrogels, and their size can shift from several nanometers to micrometers. Moreover,
hydrogels can also be categorized as non-responsive and stimuli-responsive hydrogels.
Non-responsive hydrogels, as the name indicates, are just the materials which swell
upon water ingestion, while the stimuli responsive gels swell as a function of changes in
the environment [50, 58, 59]. Hydrogel can respond to temperature [55], pH value [57],
ionic strength, light, electrical field and biomolecules. The responsive property of the
hydrogels is acquired from the nature of the polymer utilized as a part of forming the gel
and/or any post-polymerization adjustments that are made [50]. In the next section, a
brief overview of stimuli-sensitive polymers and differences between micro and nanogels
will be highlighted.
1.3.3.3 Stimuli-Sensitive Polymers
The utilization of the stimuli-sensitive polymers in manufacturing hydrogels has prompted
numerous intriguing applications such as targeted drug delivery. Poly(N-isopropylacryl-
amide) (pNIPAm) which is constructed from the monomer N-isopropyl-acrylamide (NI-
PAm) has been extensively studied as a stimuli-sensitive polymer [60]. Heskins et al. has
observed that the phase transition of pNIPAm is endothermic and is driven by entropy.
Owing to this, pNIMAm is extensively employed to produce responsive hydrogels [61].
Balance between solvent-solvent, solvent-polymer, and polymer-polymer interactions has
a relation with the behaviour of any polymer in the solvent [50]. It is possible to switch
the polymer solvation by either strengthening one of these interactions or by weakening
another. Figure 1.11 depicts this.
Figure 1.11: Changes in solvent properties induce phase transition in stimuli-sensitive
polymers [50]
Amide-chains in the pNIPAm form hydrogen bonds with the water, on the other hand,
the isopropyl groups gather as side chains prompting hydrophobic structuring of the
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water. This structured water prompts polymer-polymer interactions due to hydropho-
bic effect which is entropically driven [60]. When the polymer-solvent interactions are
greater than the polymer-polymer interactions, pNIPAm will have random-coil structure.
There will be a breakage of hydrogen bonds at high temperature leading to entropically
driven release of the bound water, which results in the formation of globular polymer
structures. At this point, hydrophobic interactions between polymer-polymer dominate
the polymer-solvent interactions which cause phase separation of the polymer phase.
The temperature at which this phase separation happens is called lower critical solution
temperature (LCST). Study of pNIPAm phase transition by Wu et al. stated that tran-
sition from random coil state to globular form is not first order, rather, there are other
thermodynamically stable conformations present intermediately [62, 63].
1.3.3.4 Microgels and Nanogels
Colliodally stable hydrogels in the micro and nano size range are termed as micro and
nano gels respectively. Properties of micro or nano gels are almost identical to that
of macrogels except for size related properties. Microgels also have other attributes
of colloidal dispersions, like zeta potential, and can frame ordered colloidal phase along
with the properties mentioned above [50]. Studies performed by Wu et al. have indicated
differences in the phase behavior of the macro- and microgels, for example volume phase
transition temperature (VPTT which is defined as volume phase transition of polymer
gels at and above their phase transition temperature) of microgels is a bit higher than
the LCST of pNIPAm.
In addition to this, transition region in case of micro/nanogels is less sharp than that
of the macrogels [64]. The possible reason for this kind of transition is due to more
heterogeneity in the structures of the microgels compared to macrogels. Microgels have
regions of long and short sub chains, therefore when temperature is raised above the
VPTT, the areas with the longer subchains undergo collapse at lower temperature com-
pared to the areas with shorter subchains. It can be inferred from the discussion above
that phase transition from a microgel is a combination of the phase transitions of di-
verse sub-networks in the system, this particular behavior is also shown by the core-shell
structured microgels [65].
1.3.4 Synthesis Methods for Hydrogels
There are several techniques to synthesize hydrogels, the most widely used will be dis-
cussed here. It is important to mention here that the method used to synthesize nanogels
is purely dependent on the end use and required application of the produced nanogels.
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1.3.4.1 Emulsion and Precipitation Polymerization
Surfactant-free emulsion polymerization or precipitation polymerization is the most
widely used method to produce thermosensitive hydrogel systems. In this technique,
NIPAm and the cross-linker commonly, N,N- methylenebisacrylamide (BIS), are dis-
solved in water. After purging the solution with N2 gas and heating above the pNIPAm
LCST(reaction temperature being normally around 70 oC), ammonium persulfate (APS)
or potassium persulfate (KPS) type initiators are added to this solution. This process
can provide particles with narrow size distribution if performed precisely [50]. High
temperature is required in this method to form sulfate radicals which are responsible
for the initiation of polymerization. This method is based on homogeneous nucleation.
After initiation, sulfate radicals react with NIPAm monomer which is followed by radical
propagation and chain growth. As the polymerization temperature is greater than the
LCST of the polymer, chains collapse upon themselves after reaching a critical length to
form precursor particles, that is why this method is also called precipitation polymeriza-
tion. Growth of precursor particles takes place by aggregation either with other particles
or with growing monomer. The hydrogels are stabilized with the charge from initiator
after they have attained a critical value. Figure 1.12 depicts the possible mechanism for
precipitation polymerization.
Figure 1.12: Suggested mechanism for precipitation polymerization of nanogels [50]
Precise size control of the hydrogels can be achieved very easily. For instance, smaller
hydrogels can be produced by stabilizing the precursor particles in the earlier stages
of the reaction. Sometimes it is reasonable to add ionic surfactants to the system to
transmit colloidal stability during the earlier stages of the reaction as there is insufficient
charge accessible from the initiator to stabilize small precursor particles. On the other
hand, to get larger particles, surfactant concentration can be decreased [50]. Percipi-
tation polymerization is also useful to add co-monomer in the hydrogel. pH responsive
hydrogels are formed by co-polymerization of ionic monomers like acrylic acid (AAc)
with pNIPAm [57, 66, 67].
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1.3.4.2 Core-Shell Structured Systems
There are two kinds of core-shell hydrogels; one in which both core and shell are made
of hydrogel-like materials and the other in which core is not made with hydrogel while
shell is constructed from hydrogel. In the second class, polystyrene, silica or gold is
normally used as a core. In the first case, two-stage polymerization protocols have been
used to produce these kinds of hydrogels [57]. In these strategies, radial distribution of
the functional groups in the particles is allowed by adding polymer shell having the same
or different structure as that of the core into the preformed core particles. In a common
synthesis approach, shell monomer solution is added to the heated (at 70 oC) preformed
pNIPAm core particles. After reaction is completed, resulting mixture is allowed to cool
and thereafter separated by filtration. Mechanism followed by this reaction is somehow
similar to that for the core hydrogels. As the reaction occurs at a temperature higher
than VPPT of the core particles, the particles which are formed are in collapsed form.
These hydrophobic collapsed particles attach to the growing oligomers, resulting in the
production of shell [50]. Core-shell particles which are formed by this approach can show
very exciting properties [56, 68, 69]. These particles can demonstrate multiple phase-
transition behaviours with temperature and/or pH as shell can be constructed utilizing
distinctive co-monomers [57, 68, 69].
1.3.5 Swelling properties of hydrogels
Monomer used to synthesize hydrogel will decide the nature of the produced hydrogels.
When hydrogels are produced by using pNIPAm, they show thermoresponsive behaviour
similar to pNIPAm. Hydrogels display volume phase transition temperature (VPTT)
at around the LCST of pNIPAm [70]. When temperature is raised above the VPTT,
hydrogels undergo transition from a hydrophilic state which is the swollen state to a
hydrophobic or the compressed state. Cross-linking density, hydrophobic-hydrophilic
balance, ionic strength and solvent composition are typical factors which can influence
the VPTT of the gels.
Hydrogels depict pH-dependent swelling when they are synthesized from ionic monomers.
Acrylic acid is the most widely used ionic monomer. The gel swells at pH > pKa of
the acid co-monomer, due to de-protonation of acrylic acid segments which prompts
Coulombic repulsion (electrostatic repulsion) between the carboxylate anions. This re-
pulsion increases the osmotic pressure inside the particles which leads to increase in
the swelling of the polymeric system. Therefore, equilibrium gel-swelling volume is a
balance between the osmotic pressure of the polymer system which is administered by
polymer-solvent interactions, and the elastic properties of the polymer network [71].
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1.4 Advantages of NPs
Radical change in novel drug delivery systems is driven by the persistent development
of the pharmacological and therapeutic properties of the drug. This rising need of drug
delivery systems is tackled by analysing a broad spectrum of therapeutic nanocarries
due to their improved performances [6]. NP based drug delivery systems have certain
advantages such as longer circulation half-lives, minimum side effects and better phar-
macokinetics [2].
Nanoscale size delivery systems are popular among formulation scientists. The most
significant reason for their popularity is the increase in the surface area because the ratio
of number of molecules to the total number of molecules or surface atoms is increased.
This increased surface area is helpful in binding, and in adsorption of drugs, probes and
proteins [2].
Another important advantage of NPs is the easy control of their size, morphology and
surface charge. NPs can be modified with different systems which can alter the particle
degradation and hence drug delivery and targeting properties. Ability of NPs to release
drug is dependent on their size and proper surface modification [72].
The transport mechanism is also guided by the NP properties and their surface modi-
fication Endocytosis is a more effective transporting mechanism than passive targeting
in which case, NPs extravasate through leaky vasculature around tumour tissues. On
the other side endocytosis is based on activation energy where there is interaction and
collision between the NPs and cells. In order to facilitate greater interaction with the
negatively charged cell membrane, NPs should be modified with positive charge. It is
concluded from the above discussion that size, surface charge and hydrophobicity of NPs
are important for the uptake of drugs incorporated with NPs. Size is also important for
intracellular uptake within the cells [73].
Moreover, NP based drug delivery systems increase dissolution rate of drug, decrease
drug dosage and help avoid early loss of drug by rapid clearance and metabolism [2].
Figure 1.13 summarizes the significant advantages of NP based drug delivery systems.
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Figure 1.13: Advantages of NPs based drug delivery [6]
1.5 Surface Modification of NPs
Surface modification of NPs has several advantages, most important of them are (i)
controlling the growth of NPs by stabilizing the NPs and directing their shapes during
the growth process (ii) incorporating functional groups on the surface (iii) enhancing
applications of NPs by increasing their solubilisation in different solvents (iv) modify-
ing the optical, electronic, spectroscopic and chemical properties of the NPs, whereby
allowing wide scale application possibilities (v) altering the capability of NPs to target
the desired chemical, physical, or biological environments, (vi) improving chemical and
mechanical functioning for example shielding against oxidation (vii) decreasing toxicity
[74].
For example, in case of cancer treatment, multifunctional NPs can be employed to
co-deliver proteins, small molecule drugs and genes like DNA and siRNA which are
therapeutic agents [75–77]. These multifunctional NPs carrying vector molecules like
peptides having capability of identifying tumor cells, have the ability to pass through
cancer cell barriers due to permeability and retention (EPR) effect [78–80]. Further,
they can preferably stay within target cells for longer periods. As a result of this effect,
these NPs have the ability to deliver more drug to the cancer cells. Surface modification
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can also equip NPs with imaging modalities which provide diagnostic capacities like
optical and magnetic resonance imaging [81–83]. In addition to this, surface function-
alization with ligands can particularly pin point the receptors on the surface of the cell
for targeted drug delivery. This is very helpful in cancer treatment [84–86]. Compact
layer of endothelial cells which surrounds the brain that is blood-brain barrier (BBB),
can be crossed by functionalized NPs to deliver specific payloads [87, 88].Figure 1.14 a)
and b) represent multifunctional NPs.
Figure 1.14: a) Figure illustrating targeted drug delivery and bioimaging function-
alities of multifunctional NPs [89] b) Multifunctional NPs, surface modification with
different functional particles [74]
Surface functionalization with PEG is very helpful in avoiding immunogenic reactions
which refers to bio-acknowledgment and elimination of nanocarriers by the immune
system. This surface functionalization with PEG enhances the circulation time of the
drug and decreases the clearance rate by deceiving the phagocytic cells of the immune
system like macrophages, liver cells and spleen red pulp macrophage cells whereby, giving
stealth properties to NPs. These cloaking properties forbid the adsorption of opsonins
at the NP surfaces [90]. Enhanced immunogenicity of NPs through functionalization is
depicted in Figure 1.15
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Figure 1.15: Enhanced immunogenicity of NPs through functionalization [90]
1.6 PEGylated NPs
As mentioned previously, coating of magnetic and polymeric NPs with hydrophilic poly-
mers like PEG, offers several advantages. PEGylation is an extensively used procedure
to enhance the half-life time of nanocarriers, through cloaking properties and steric
stabilization. Surface functionalization of nanosystems is done with PEG by either
conjugation, grafting or adsorption [90]. Foreign particulate matter in body fluids are
instantly covered with immunoglobulins igG and igA and the supplement proteins C3b
C4b opsonins, this process is called opsonization. Opsonins stamp the particular sub-
stance for phagocytosis through their acknowledgment by Fc receptors (protein present
on the surface of cells which enhance the protective functions of the immune systems)
on phagocytic cells, for example, macrophages. To avoid the adsorption of opsonins at
the surface of NPs, they are functionalized with PEG. Hydrophilicity of the PEG makes
this possible by attracting water molecules to NP surface which ultimately contributes
to invisibility of NPs to phagocytic cells [90]. This enhances the particle circulation time.
Moreover, owing to inflammatory reactions caused by the tumor, pathological tissues
have large permeability; this enhanced life time of NPs in plasma contributes towards
more accumulation inside the tumor and more effective drug release. The vicinity of the
polymer at the surface can likewise stablize particles, abstain them from agglomeration,
provide better bioavailability and reduce toxicity [91]. Efficiency of internalisation of
drug carrier is enhanced by modification with PEG, for example PEG-coated MNPs
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are effectively internalized by cells through endocytosis. Also surface functionalized
gold NPs coated with PEG provide effective internalization in endosomes and cytosol
[29, 92, 93]. Effect of PEG functionalization is shown in Figures 1.16 a) and b).
Figure 1.16: Effect of PEG functionalization on NP (A) Process of opsonization (B)
PEG functionalized NP [90]
PEGylated nanogels have also shown reduced protein adsorption on their surfaces. Non-
PEGylated nanogels have shown greater protein adsorption in their collapsed state as
compared to the swollen state because nanogels become hydrophobic in their de-swollen
state above VPPT, resulting in hydrophobic adsorption of proteins [94, 95]. However,
surface modfication of nanogels with PEG reduces the protein adsorption at collapsed
state. PEG integrated to PNIPAm has indicated reversible temperature dependent
swelling/de-swelling transitions. It is additionally vital to mention that introduction
of PEG expands the microgel VPTT, for example, 40 wt % PEG incorporation to the
BIS cross linked pNIPAm, shifts the VPTT from 31 oC to 36 oC [95]. In addition
to this, phase transition phenomena occurred over a wider temperature range. PEG
incorporation to the nanogels enhances the hydrophilic composition of the nanogels,
therefore more thermal energy is required by the particles to experience phase separation
from the aqueous environment which is the suggested reason for the above phenomena
[95].
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1.7 Polymer-NPs Hybrids
Combination of inorganic and polymeric NPs offers great advantages in drug delivery
application. Hybrids of polymeric and inorganic NPs offer magnetic, optical, thermal
and pH responsive behaviour and steric stability in a single drug carrier. Basic aim of
this research is to highlight the superiority of polymer-NP hybrids as drug carriers.
1.8 Administration Routes of NPs
In pharmacology, the path through which a drug, fluid or any other substance enters
the body is called route of administration. Route of administration can significantly
influence the pharmacokinetic properties such as adsorption, distribution, metabolism
and excretion of a drug [6]. Different routes of drug administration are shown in Figures
1.17 (a) and (b). Toxicity might vary with different modes of administration of the drug
[96]. Also, some routes might not be feasible for particular drug delivery scenarios. For
instance, oral delivery of drug incorporated in the NPs gives better bioavailabilty and
biodistribution for insulin loaded NPs; but in case of oral protein and peptide delivery,
poor oral bioavailabilty is still an issue. Oral administration of polyacid should be
protected from low pH in the stomach, because low pH will influence the drug release
rate and swelling of drugs; whereas, higher, pH in small intestine will ease drug release
in gastrointestinal tract due to dissociation of acid at higher pH [97, 98].
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Figure 1.17: a) Routes of NP administration and their advantages and disadvantages
[96] b) Important routes of drug administration based on NPs [99]
1.9 Non Targeted Drug Delivery
In this type of drug delivery, drug is not targeted to the specific cells. Drug is introduced
in-to the body using conventional methods of drug delivery.
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1.10 Targeted Drug Delivery
It is very important that drug carriers should have specific quality to avoid the release
of drug to the healthy cells which can cause serious side effects. Drug carrier should
be specific so that it will attack the specific site in the body to cure the damaged cells.
Important to consider in the design of drug carriers is how they will be received by the
cells with which they need to interact. Today most of the research in the field of drug
delivery systems is focused on targeting drugs to the diseased site [50, 100]. Targeted
drug delivery reduces the toxic effects caused by the drugs attacking the cells other
than which are affected by disease. Effectiveness of the targeted drug delivery system
depends on the ability to hold the drug in the polymer, to avoid disturbance to the
immune system, to specifically target the cells and in the end to release the drug to the
specific cells in a controlled manner. Many factors can affect the targeted drug delivery
like body’s response to the drug which should be considered.
1.11 Active and Passive Targeting
Targeting can be classified as active and passive. NPs having long circulation in the body
are able to explore structural abnormalities in the vasculature of tumors and infectious
sites. Passive targeting is mostly due to enhanced permeability and retention (EPR)
effect. This effect is based on the accumulation of drug carriers to the targeted cells due
to extravasation through leaky vasculature, followed by retention in the cells and final
drug distribution in the cells. Passive targeting or non-specific accumulation happens for
NPs having size in the range of 10-500 nm diameter. Information about the distribution
of drug is required to enhance this effect [29].
Active targeting is based on the recognition of specific diseased tissue and accumulation
of NPs and release of drug to the specific target site. This happens because of conjugation
of targeting molecule that has high affinity to the overexpressed molecules present in
affected cells. For active targeting, it is important that target and drug carriers are close
to each other which cannot be achieved easily[29, 50].
In the next sections, different drugs used in this study are presented along with loading
and release methods and release kinetic models.
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1.12 Drugs Studied
Physico/chemical properties of three different drugs chosen based on their aqueous sol-
ubility are highlighted in the next sections.
1.12.1 L-dopa
L-Dopa (3,4-Dihydroxy-L-phenylalanine) is an amino acid and hormone, it is formed
naturally in humans, animals and plants. Synthesis of L-dopa is done from amino acid
L-Tyrosine. L-dopa is used to treat Parkinson’s disease as it is considered a psychoac-
tive chemical. It is also used to treat other abnormal conditions such as lower levels of
neurotransmitters (Dopamine). Dopamine cannot pass through the blood-brain barrier
and should be synthesized in the brain. L-dopa can cross this blood brain barrier; after
crossing the barrier, it is converted to dopamine, which enhances level of pleasure in-
ducing hormones inside the brain[101]. L-dopa therapy for the treatment of Parkinson’s
disease is shown in Figure 1.18.
Figure 1.18: L-dopa therapy for the treatment of Parkison, disease [101]
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NPs loaded with L-dopa can pass through blood brain barrier more efficiently and can
give better results by targeting the drug to the desired site of action. Molecular weight
of L-dopa is around 197.19 g/mol. It is slightly soluble in water, acids and bases while
it is insoluble in ethanol. Its solubility in water is about 3.3 mg/ml[102]. Structure of
L-dopa is shown in the Figure 1.19. Characteristic UV-Vis peak for this drug is reported
at 281 nm.
Figure 1.19: Structure of L-dopa [102]
1.12.2 Cytochrome-C
Cytochrome C is a hemeprotein found in plants and animals. It is associated with the
mitochondria as an important part of the electron transport chain[103]. Structure of
Cytochrome C also known as cyt c is represented in Figures 1.20 A) and B),
Figure 1.20: A) Structure of cytochrome c [104] B) 3-dimensional structure of cy-
tochrome c a) ribbon illustration of cyt c with water molecule b)Tyrosine high resolution
image c) haemo’s group d) interaction of haemo’s group with histidine 18 [105]
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Proficiency of cytochrome C as a biological electron transporter is a result of its conve-
nient interconversion between ferrous and ferric states. Formation of necessary electron-
bridge between the oxygen and respirable substrate is attributed to this hydrophilic
protein. Owing to this, it is viewed as universal link in the respiratory chain[106].
Figure 1.21 shows electron transport protein complex.
Figure 1.21: Electron transport protein complex [106]
Apoptosis is the programmed cell death which involves the characteristic cell changes
and cell’s death. Diseases like cancer, immune and neurodegenerative disorders can be
possible if process of apoptosis is disturbed. Capases(cysteine proteases) are responsible
for the execution of apoptosis, cytochrome c activates capases. In this pathway, a number
of apoptotic stimuli cause cytochrome c discharge from mitochondria, which thus incites
a progression of biochemical reactions causing caspase initiation and consequent cell
death. Thus, cytochrome is important for apoptosis process[107].
Isoelectric point of cyt c is roughly at pH 10, and it is not affected by the low pH and its
solubility in water is 100 mg/ml. Small size and overall positive charge of the cytochrome
c is important in some applications[108]. Characteristic UV-Vis peak for this protein is
reported at around 409 nm.
1.12.3 Coumarin
Coumarin(1,2-Benzopyrone or 2H-Iibenzopyran-2-one,) and derivatives of coumarin are
extensively dispersed throughout the nature. Coumarin has 0.10 mg/ml solubility in
water. They display fruitful and broad biological actions. The name Coumarin origi-
nated from the French word coumarou used for tonka bean. This is due to the presence
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of the coumarin in seeds, roots and leaves of several plants especially in tonka bean in
large concentrations. Natural and synthetic coumarin are widely available and can be
divided into a number of subclasses. Some natural coumarin derivatives include (6,7-
dihydroxycoumarin, 4), warfarin and psoralen. Mostly coumarin is classified by reviews
as simple coumarin(for example, coumarin, 1), linear and angular furanocoumarins, lin-
ear and angular pyranocoumarins. Coumarin can also be classified by using biogenetic
approach using number of nuclear oxygen atoms as a basis. Structure of coumarin used
in the study is given in the Figure 1.22
Figure 1.22: Structure of Coumarin[109]
Several therapeutic applications of coumarin derivatives include photochemotherapy,
anti-tumor and anti-HIV cure. In addition, they are used as stimulant for the central
nervous system and as antibacterials. The most fascinating application of coumarin is
the striking effect against breast cancer. Recent studies on the antitumoral action of
coumarin derivatives affirm that it is possible to manage coumarin-estrogen conjugates
by conjugating coumarin substrate with 17β-estradiol. This conjugate exhibits growth
stopping exercise in different breast cancer cell lines[110]. Characteristic UV-Vis peak
for this protein is reported at around 277 nm.
1.13 Loading and Release of the drugs
Effectiveness of drug delivery systems is based on the efficient drug loading and release
properties [111]. Drug loading is incorporation of the drug into/onto a nanocarrier [112].
Drug encapsulation or conjugation with the nanocarriers can shield it from inactivation
and also help drug to stay active for longer periods. Furthermore, there is a decrease
in the drug toxicity and flexibility in administration modes. Drug release however is
opposite in the sense, that drug molecules are released from the carriers and then perform
pharmacological action. Physico-chemical properties of drug and matrix, interaction
30
Chapter 1. Introduction 1.13 Loading and Release of the drugs
between the drug, matrix and the environment establish a relation between drug loading
and release as both of these phenomena are dependent on them [111]. In order to obtain
successful drug loading, it is important to have good compatibility between the drug
molecule and the carrier, leading to reasonable loading degree and proper location of
the drug molecules in/on the drug carrier. Payload molecules should maintain stability
during loading, storage and release. This is important for the case of proteins, peptides
and oligonucleotides, because these systems can lose their biological activity over time
and owing to environment [113]. It is also important to mention that sustained controlled
release is vital in providing required drug concentration to the target sites.
1.13.1 Loading and encapsulation efficiency
Primarily there are two methods by which drug is loaded onto the NPs, one is incorpo-
ration of the drug during the NP production while in the other method drug is adsorbed
to the NPs after their formation [114, 115]. Apart from these methods, breathing in
mechanism is also used for hydrogels. In this method, polymers are imbibed with a con-
centrated drug solution whereby the hydrogel pores are filled up with the drug solution.
Drug loading can also be performed by chemically conjugating the drug with the NPs.
One example of this technique is formation by solvent diffusion method of conjugated
doxorubicin-PLGA and doxorubicin-loaded PLGA NPs [116].They can be calculated by
using the following formulae,
Loading efficiency =
Mass of drug loaded
Intial mass of drug
× 100 (1.1)
Encapsulationefficiency =
Mass of Drug loaded
Mass of NPs
(1.2)
Irrespective to the loading methods, loading efficiency and encapsulation efficiencies are
two important numbers that define loading capabilities. Drug loading and encapsula-
tion efficiencies are dependent on degree of solubility of the drug in the solution and the
matrix. Drug solubility is related to molecular weight of the matrix, its composition, in-
teraction between drug and polymer and existence of end functional groups like ester or
carboxyl in drug or in matrix material [117–119]. For some systems, it is observed that
as the alkyl chain length becomes longer, the attraction towards the drug is increased.
Therefore, the adsorption capacity has a relation with the hydrophobicity of the poly-
mer and specific area of the NPs [120]. In addition to that, surface-active agents and
stabilizers also have an influence on the drug loading [121]. It is important to mention
here that various factors are crucial for hydrogel swelling/deswelling kinetics- size, cross
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linking density and network homogeneity[122–127]. Higher cross-linking density causes
a decrease in drug release and swelling response. Bromberg et al. indicates with the
example of poly(acrylic acid) based systems that the swelling kinetics decreases with
increase in cross-linking density [124]. Swelling kinetics becomes slower and also degree
of network swelling decreases as the microgels become more hydrophobic. Hydrophobic
modification of the PNIPAm microgels decreases their swelling kinetics as studied by
Bysell et al [94]. Moreover, ratio of cross linker and AAc has an effect on the loading of
drug onto PNIPAm/AAc particles [94]. Heterogeneity of microgels is also of significance
for loading and release kinetics in microgel frameworks. Studies performed by Chu et al.
indicate that faster temperature response is achieved with the microgels having voids.
Fine tuning of phase transition kinetics is also possible by regulating the size and count
of the voids. Thus, significance of microgel polydispersity and structural heterogene-
ity are the driving force to establish methods which provide monodisperse and uniform
microgels [128].
1.13.2 Drug and carrier Interaction
Increased interactions between drug and carrier enhance the loading and encapsulation
efficiencies. Hydrophobic and non-electrostatic interactions are of vital significance for
loading of amphiphilic drugs[94]. However, ionic interactions between drug and the
carrier are the most popular kind of interaction. Introduction of ionic interface between
drug and matrix provides improved drug loading as indicated by several studies [93, 94].
Hydrophillic interfaces have given better results for adsorption and release. Hydrophilic
hydrogels provide easier loading of hydrophilic drugs and charged bio-macromolecules.
Depending on the interaction strength, partially hydrophilic hydrogels will not induce
conformational changes and aggregation of proteins. As a result of this, hydrophilic
hydrogels enable bio-macromolecules to sustain their biological effects [93, 94].
1.14 Release of the drug
There are a number of factors which govern the drug release rate like (1) drug solubility
(2) desorption of the adsorbed drug (3) diffusion of the drug from the NP matrix (4)
NP matrix erosion (5) combined effect of erosion and diffusion processes. Subsequently;
solubility, diffusion, and biodegradation are important parameters of the particle matrix
which oversee the release process [114]. Drug release can also be influenced by the loading
efficiency of drug and NP size, smaller particles will provide larger initial burst release
as compared to larger particles [129]. If the drug is evenly distributed (for example in
case of nanospheres), erosion or diffusion of the matrix will cause the release of the drug.
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However diffusion process will be responsible for the drug release, if the diffusion of the
drug is faster compared to the matrix erosion. Moreover, if the interaction between
drug and particle matrix is weak and/or drug is attached to a large surface of the NPs,
then burst release can occur [130]. Research studies have shown that mechanism of
incorporation has an influence on the release profile. For instance, if the incorporation
method is utilized for drug loading, then the framework has a comparatively little burst
release and constant release attributes [131]. In contrast for coating of NPs with the
polymer, the release of the drug is regulated through diffusion of the drug from the
polymeric system. Coating of NPs with different layers can work as an obstruction
to the drug release, causing drug diffusion and solubility in or over the polymer layer
act as deciding factors. Besides, release rates can be additionally influenced by ionic
interactions between the drug and subsidiary constituents. Least water soluble complex
formation takes place due to interaction between the drug and subsidiary constituents,
which ultimately effects (slows) the release rate of the drug with more or less no burst
release effect [132].
1.14.1 Release Models
Mathematical modeling provides a platform to investigate the mass transfer mecha-
nisms that are involved in the control of drug release [133]. There are few good reviews
on mathematical modeling for drug release from bio-erodible polymeric delivery frame-
works, hydrogel systems, degradation-controlled drug delivery processes [134]. The most
vital systems, for drug transport from polymeric grids are diffusion, erosion and degra-
dation [134]. Brief summary of these systems is condensed in the next sections.
1.14.1.1 Empirical Models
Power law equations can be employed to perform the modeling of the release kinetics.
Use of empirical models is not very difficult and it is possible to clarify transport mech-
anisms utilizing proved empirical rules. Contrarily, these models do not give further
bits of knowledge into more complicated transport systems. In addition, these models
may come up short whenever there is a requirement for considering particular physico-
chemical procedures [135].
1.14.1.2 Diffusion-based Models
Drug release for slab-like planes can be modelled using the given mathematical equation
based on Fick’s second law of diffusion.
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Mt
M∞
= 4
(
Dt
Πh2
) 1
2 (1.3)
Here Mt, represents the quantity of drug released at time t, while M∞ is the amount
of drug release as time approaches infinity. Thickness of the drug delivery device is
represented by h, diffusion coefficient of the drug in the polymer grid is given as D.
This equation is valid for the condition 0 ≤ MtM∞ ≤ 0.6, which accounts for the first 60
% of cumulative release.
The equation given above is applicable only when the assumption of no deterioration
or mass loss of the material grids is met. In order to anticipate the release profile, it is
important that diffusion coefficient (D) inside the polymer grid ought to be accessible.
This problem can be resolved by using nuclear magnetic resonance, and fluorescence
correlation spectroscopy to measure diffusion coefficients [136].
1.14.1.3 Degradation-based models
Model based on polymer dissolution
The process in which polymer starts to release drug to the encompassing liquid, in the
vicinity of a thermodynamically suitable solvent is known as polymer disintegration or
dissolution [137]. Solute diffusion as well as polymer dissolution can regulate the dis-
charge of the drug from these kinds of polymeric frameworks. On the basis of molecular
mechanism, Narasimhan and Peppas constructed a model for polymer dissolution [138].
In equation 1.4 (S-R) is gel layer thickness,
(S −R)
B
− A
B2
ln
{
1− B
A
(S −R)
}
= t (1.4)
In equation 1.4 parameter A and B are given as,
A = D (v1,eq − v∗1)
[
v1,eq
v1,eq + vd,eq
+
1
v∗1 + v∗d
]
+Dd (v
∗
d − vd,eq) (1.5)
B =
kd
v1,eq + vd,eq
(1.6)
The equation for cumulative release is
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Md
Md,∞
=
vd,eq + v
∗
d
2l
.(
√
2At+Bt) (1.7)
In equations 1.5, 1.6 and 1.7 D is define as diffusion coefficient for the solvent while Dd
represents the drug coefficient for drug. While characteristic concentrations for solvent
and drug are given as v∗1 and v∗d respectively. Equilibrium concentration for drug and
solvent are represented as vd,eq and vd,eq and rate of polymer dissolution is given as kd .
Model based on Erosion
Systems in which drug release is based on the erosion of the polymeric surface, Hopfen-
berg’s model can be suitable. In Hopfenberg’s model, zero-order surface dissolution of
the drug is defined as the rate limiting discharge (of the drug) step. Equation based on
this model is applicable on constructs like spheres, cylinders and slabs.
Mt
M∞
= 1−
(
1− k0t
c0a
)n
(1.8)
In the equation 1.8, the amount of drug released after time t is given by the ratio of Mt
and M∞. Shape factor is represented as n in the equation. Value of n varies for different
shapes and n=1 for slab, n=2 for cylinder and n=3 for spherical geometries [139].
There are several shortcomings of the Hopfenberg’s model. One of them is deviation
of the estimated values from the equation for the cylinderical tablet [140]. Katzhendler
et al. proposed a model for the release of drug from erodible systems in an attempt to
rectify shortcomings in Hopfenberg’s model. Radial erosion as well as axial erosion are
considered in this model [141].
Mt
M∞
= 1−
(
1− kat
c0a
)2(
1− 2kbt
c0b0
)
(1.9)
In the equation 1.9, ka and kb are radial and axial erosion rate constants respectively.
Initial radius of tablet is a0 while b0 is the thickness of the tablet.
1.14.2 Drug Release from swellable systems
Higuchi equation in its general form is given as
Mt = k
√
t (1.10)
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Thin film Cylinder Sphere Drug release mechanism
exponent, n
0.5 0.45 0.43 Fickian diffusion
0.5< n <1.0 0.45< n <0.89 0.43< n <0.85 Anomalous transport
1.0 0.89 0.85 Case-II transport
Table 1.1: Values of n for different geometries and drug release mechanisms from
polymeric delivery systems [142].
In the equation 1.10 Mt is cumulative amount of drug which is released while k is rate
constant which is equal to,
k = A
√
2CiniDcs (1.11)
In equation 1.11 Cini initial concentration of the drug and cs is the drug solubility.
Mathematical equation based on Fick’s second law of diffusion is given in equation 1.3
which governs Fickian diffusional release from polymeric samples. Drug release from
swellable systems is not always in- accordance with the Higuchi’s or the zero order
equation. Majority of drug release processes from glassy polymers is defined by two
limiting cases, that is combination of Fickian and case II transport mechanism (specific
transport mechanism) [142, 143]. Case-II transport mechanism is given by Mt = k2t
where k2 = case II transport rate constant represents how the polymer relaxation will
effect the molecules movement with in the matrix [144]. It is based on two assumptions-
a boundary is formed between glassy and rubbery phase of the polymer and boundary
moves at constant velocity. Mathematically this behaviour is defined by combining
diffusional-controlled and visco-elastic relaxation-controlled drug release
Mt
M∞
= k1
√
t+ k2t (1.12)
k1 and k2 are constants. In more general form this equation can be described as,
Mt
M∞
= ktn (1.13)
In the equation 1.13 k is the rate constant constants and n is the diffusional exponent.
when n is equal to 0.5 then drug release is governed by Fickian drug diffusion and
n=1 defines the relaxation drug transport. Whereas, the values of n between 0.5 and 1
describe anomalous drug transport.Table 1.1 indicates different values of n for different
geometries and drug release mechanisms from polymeric delivery systems [142, 143].
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1.14.3 Drug Release from Nanogels
Drug can be released from nanogels as a consequence of diffusion, degradation of nanogel,
pH shift, presence of counterions in the environment, external energy responsible for
transition, or, due to environmental changes [111].
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2.1 Materials
Iron pentacarbonyl (Fe(CO)5 99.99%), octadecene (ODE, 90%), oleylamine (OAm,
70%), chloroauric acid (99.999%), sodium citrate, O-[2-(3-Mercaptopropionylamino)ethyl]-
O’-methylpolyethylene glycol (PEG−SH) of weight 5000 Da, 3,4-Dihydroxy-L-phenylalanine
(L-dopa), Coumarin, Cytochrome C from bovine heart were purchased from Sigma
Aldrich, and Hydrogel (pNIPAm/AAC).
Characterization techniques used are ultraviolet visible spectroscopy (UV-vis), Dynamic
light scattering (DLS)and scanning transmission electron microscopy (S(T)EM), while
mini centrifuge was used for centrifuging particles.
2.2 Methods
2.2.1 Synthesis of Fe@Au
The Fe@Au NPs were synthesized using a method developed by S. Bandyopadhyay [145].
For the synthesis of Fe@Au NPs, stock solution of 10mM sodium citrate was made,
(calculations are given in the appendix A). After that 5 mg, of Fe NPs were added in
10ml of 10mM sodium citrate solution in a tube and this mixture was sonicated for
2 hrs at 80 oC. After 2 hours, most of the Fe NPs were dissolved in sodium citrate
solution and this brown coloured solution was removed from sonicator. A 50ml reactor
was put in an oil bath, and this citrate stabilized Fe solution was added to the reactor
and maintained at 70 oC with stirring at 200 rpm. Meanwhile stock solution of 1.5mM
chloroauric acid was made and 10 mL of this solution was added drop wise in the reactor
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containing citrate stabilized Fe NPs solution. Stirring was increased to 500 rpm, and
these reactants were allowed to react for 20 minutes. After about 8 minutes reaction,
mixture turned into purplish red solution and after 20 minutes reactor was removed
from oil bath and the solution was cooled down to room temperature.
This reaction mixture was centrifuged at 14,500 rpm for 10 minutes. Fe@Au NPs were
re dispersed in MQ water. Concentration of the produced Fe@Au NPs was calculated
using simple concentration measuring technique, and stored for further use. Setup for
the formation of Fe@Au NPs is shown in the Figure 2.1.
Figure 2.1: Setup for the formation of Fe@Au NPs
2.2.2 Coating of Fe@Au NPs
Fe@Au NPs were coated with hydrogel type A by method 1 and 2 and type B by method
2, PEG-SH (term PEG is used throughout this study ), and combination of PEG and
hydrogel. Coating of Fe@Au with hydrogel will be discussed in the next sub section.
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2.2.2.1 Coating of Fe@Au with Hydrogel Type A (Method 1)
Solution of hydrogel having concentration of 1mg/ml was prepared in MQ water. In a
separate vial, Fe@Au NPs stock solution was diluted to 10mg/ml concentration. To coat
Fe@Au NPs with hydrogel, 500µl of Fe@Au(10mg/ml) was added to 3 ml of hydrogel so-
lution(1mg/ml). After adding Fe@Au NPs to the hydrogel solution, 1.5 ml of MQ water
was added to this mixture. Then this mixture was placed on the stirrer at 500 rpm for 2
hours. Reaction solution was removed from the stirrer after 2 hours and centrifuged for
20 minutes at 14,500 rpm. After centrifugation, supernatant were removed and Fe@Au
NPs coated with hydrogel was re dispersed in 1 ml of MQ water. This Fe@Au Hydrogel
sample was thereafter stored in the refrigerator for further use.
Safety and precaution relevant to this step is accurate measurement of the hydrogel
weight using weighing machine, as it is sometimes difficult to measure the weight of
hydrogel due to charging.
It is important that after mixing Fe@Au, Hydrogel and MQ water, the mixture is placed
on the stirrer as quickly as possible, because reaction starts immediately after mixing.
Magnets used for stirring should always be washed with MQ water before using them.
Special care is needed while removing supernatant, it should be as accurate as possible
and supernatant should not contain any Fe@Au Hydrogel NPs.
2.2.2.2 Coating of Fe@Au with Hydrogel Type A (Method 2)
In order to coat Fe@Au NPs with hydrogel type A (Method 2), 3.3 mg of hydrogel
was weighed. Separately, 5 mg/ml of Fe@Au NPs stock solution was made. In the
3.3 mg of hydrogel, 2 ml of 5 mg/ml of Fe@Au NPs solution and 3 ml MQ water
were added. After that, the solution was placed on the stirrer at 500 rpm for 2 hours.
Reaction solution was removed from the stirrer after 2 hours and the resulting reaction
mixture was centrifuged at 14,500 rpm for 20 mins. After centrifugation, supernatant
was removed from the Fe@Au Hydrogel and the formed NPs were re dispersed in 2 ml
MQ water and stored in refrigerator for further use.
The main difference between the methods 1 and 2 is the difference in the addition of
hydrogel to the Fe@Au NPs solution. In method 1, stock solution of hydrogel in MQ
water having 1 mg/ml concentration was first prepared and then this solution of hydrogel
was added to the Fe@Au NPs. While in method 2; hydrogel in solid form was mixed
with the Fe@Au NPs solution without making its stock solution in MQ water.
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Safety and precautions are similar for method 2 as with method 1, however for method
2, it is important that hydrogel should be weighed carefully and exact 3.3 mg should
be added to the Fe@Au NPs solution. Higher or lower concentration might affect the
results. Figure 2.2 represents the setup for the coating of Fe@Au NPs.
Figure 2.2: Setup for the coating Fe@Au NPs
2.2.2.3 Coating of Fe@Au with PEG
PEG coating of Fe@Au was done by adding 500 µl of 10 mg/ml Fe@Au NPs and 4.5 ml
MQ water in 2 mg PEG. Afterwards, this solution was placed on the stirrer for 2 hours
at 500 rpm. Coating was completed in 2 hours and reaction mixture was removed from
the stirrer and centrifuged at 14,500 rpm for 20 mins. After 20 mins of centrifugation,
PEG coated Fe@Au NPs were separated from the residual reaction mixture by removing
supernatant. Coated NPs were then re- dispersed in 1 ml MQ water and stored in
refrigerator for further studies.
Safety and precautions are similar to the hydrogel coating as more or less same procedure
was involved in PEG coating. PEG weighing is also tricky as with hydrogel because this
white powder is not easy to handle, so extra care should be given during PEG weighing.
2.2.2.4 Coating of Fe@Au with PEG - Hydrogel
Combination of PEG and hydrogel were coated on Fe@Au to exploit combined effects
of both PEG and hydrogel. In order to coat PEG and hydrogel on Fe@Au NPs, PEG
coating was done on Fe@Au first by adding 500 µl of 10 mg/ml Fe@Au NPs and 4.5
ml MQ water in 2 mg PEG. Two samples of Fe@Au PEG were made and combined to
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give 2 ml of sample. In this 2 ml solution of Fe@Au PEG, 3.3 mg of hydrogel and 3 ml
of MQ water were added. Afterwards this sample was placed on the stirrer for 2 hours
at 500 rpm. On completion of coating after 2 hours, the solution was centrifuged using
the same conditions and redispersed in 2 ml water. Fe@Au PEG Hydrogel sample was
thereafter stored in refrigerator.
Safety and precautions are same as for PEG and Hydrogel coating. One important point
is the addition of hydrogel to the Fe@Au PEG as this might cause problem. So, it is
important to weigh the hydrogel first and then add Fe@Au PEG solution to it.
Figure 2.3: Steps for the loading of coated Fe@Au NPs
Characterization of the Fe@Au NPs before and after coating were done using DLS,
UV-vis spectroscopy, S(T)EM and zeta potential measurements.
2.2.3 Loading
Fe@Au NPs coated with different polymers were loaded with different drugs to use them
as drug carriers in therapeutic and theranostics applications. Three drugs namely, L-
dopa, Coumarin, and Cytochrome C were employed for loading studies. Procedure used
for loading studies is explained in the next section. Results were analysed using UV-vis
spectroscopy.
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2.2.3.1 L-Dopa
Fe@Au Hydrogel, Fe@Au PEG, and Fe@Au PEG Hydrogel NPs were loaded with L-
Dopa. At first 5 mg/ml Fe@Au particle concentration was used with drug concentration
of 0.5 mg/ml. For loading, 1 ml of Fe@Au Hydrogel having particle of concentration 5
mg/ml was centrifuged at 14,500 rpm for 20 minutes. After centrifugation, supernatant
was removed from Fe@Au Hydrogel NPs. Meanwhile, drug solution having 0.5 mg/ml
concentration was prepared. It is important to mention here that L-Dopa has solubility
of about 3.2 mg/ml in water at room temperature. L-Dopa is not very soluble in water
and requires some time to be completely dissolved. After L-dopa solution was ready,
1 ml of this solution having 0.5 mg/ml concentration was added to the centrifuged
Fe@Au Hydrogel NPs. Similar procedure was used for the loading of Fe@Au PEG, and
Fe@Au PEG Hydrogel. After adding drug solution to the coated NPs, three samples
were placed on the shaker for 2 hours to complete the loading. After loading, the samples
were centrifuged at 14,500 rpm for 20 minutes and the supernatant was measured in the
UV-Vis to estimate loading efficiency.
Optimization of Loading Efficiency In order to enhance the loading efficiency,
different NP and drug concentrations were used (values of loading efficiencies are given
in Appendix C). For instance, in case of Fe@Au Hydrogel highest loading was achieved
for high particle and low drug connection. The optimized results will be discussed in
result and discussion section.
Based on the drug and particle concentration used for the L-Dopa, loading studies of
Coumarin and Cytochrome c were performed.
2.2.3.2 Coumarin
As mentioned above, Coumarin loading studies were based on the L-dopa loading re-
sults. NP concentrations for Fe@Au Hydrogel, Fe@Au PEG, and Fe@Au PEG Hydrogel
which gave best results for L-dopa were used for Coumarin. while drug concentrations
used for Coumarin loading were based on the solubility of the Coumarin and highest and
lowest concentrations of L-dopa used for loading. Calculations are given in Appendix
G.
For Fe@Au Hydrogel loading, particle concentration of 5 mg/ml and drug concentration
of 20 µg/l were used. Fe@Au Hydrogel sample having a volume 1 ml was centrifuged
at 14,500 rpm for 20 minutes. After centrifugation, supernatant was removed from the
Fe@Au Hydrogel sample. Drug solution having 20 µg/l concentration was prepared and
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1 ml of this drug solution was added to Fe@Au Hydrogel NPs. After adding drug to
the NPs, the sample was placed on the shaker for 2 hours at moderate shaking rate.
After 2 hours, drug loaded Fe@Au Hydrogel sample was centrifuged and supernatant
was measured in UV-Vis.
Safety and precautions which are important for this step are, handling of coumarin
should be done carefully, as it can be toxic or harmful if swallowed. Moreover it is
important to place sample as quickly as possible on the shaker after mixing the drug
with the Fe@Au Hydrogel, because loading starts almost immediately after the mixing
of drug and Fe@Au Hydrogel NPs.
2.2.3.3 Cytochrome - C (Cyt-C)
Drug concentration of 0.1 mg/ml and 0.5 mg/ml were used for Cytochrome c loading
studies. NP concentrationS for Fe@Au Hydrogel, Fe@Au PEG, and Fe@Au PEG Hydrogel
were same as that for L-dopa and Coumarin loading studies. For Fe@Au Hydrogel, two
samples of 1 ml solution having particle concentration of 5 mg/ml each were centrifuged
at 14,500 rpm for 20 minutes. After centrifugation, supernatant was removed and 1
ml of Cytochrome C having a concentration of 0.50 mg/ml was added in one sample
while in second sample, drug solution having 0.10 mg/ml concentration was added and
samples were placed on the shaker at moderate speed for 2 hours. After 2 hours, samples
were removed from shaker and centrifuged and supernatant was measured using UV-Vis.
Same procedure was used for the loading of Fe@Au PEG, and Fe@Au PEG Hydrogel.
2.3 Release
Release was performed for Fe@Au Hydrogel, Fe@Au PEG, and Fe@Au PEG Hydrogel
systems loaded with the three drugs (Coumarin, L-Dopa, Cytochrome c) and results
were analysed using UV-Vis spectroscopy.
2.3.1 Coumarin Release
Coumarin release studies from Fe@Au Hydrogel, Fe@Au PEG, and Fe@Au PEG Hydrogel
were at first planned under three different conditions, normal pH;high temperature,
Low pH;normal temperature, high temperature;low pH. NPs and drug concentrations
used for release were same as for the loading studies. Fe@Au Hydrogel, Fe@Au PEG,
and Fe@Au PEG Hydrogel samples (3 samples for each system) loaded with coumarin
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were centrifuged at 14,500 rpm for 20 mins. After centrifugation, supernatant was re-
moved from the samples and bottom product for Fe@Au Hydrogel and Fe@Au PEG
samples were dispersed into 15 ml MQ water respectively (5 ml solution for one study).
Fe@Au PEG sample was measured in the UV-vis, afterwards pH for this sample was
measured and it was 6.8. This sample was then divided into two parts. One of 10 ml for
high temperature;low pH and normal temperature;low pH (sample 1) and other is of 5
ml for high temperature;normal pH (sample 2), this sample was placed on heating bath
at 40 oC and 500 rpm stirring. For sample 1, solution pH was changed with 0.25mM
HCl acid to 3.53. After pH change, this 10 ml solution was divided into 2 parts 5 ml
each. One sample was placed onto a heating bath at 40 oC with stirring at 500 rpm,
while to study the effect of low pH other sample was placed on the stirrer at 500 rpm.
Similar procedure was repeated with Fe@Au Hydrogel.
Release study for the above systems did not provide satisfactory results due to low
concentrations of the drug. For the third sample, Fe@Au PEG Hydrogel, it was de-
cided to increase the concentration by dispersing two loaded samples (1 ml of 100 µg/l
Coumarin dissolved in 3.75 mg NPs) of Fe@Au PEG Hydrogel into 3.5 ml MQ water.
Then it was decided to study the release for Fe@Au Hydrogel and Fe@Au PEG loaded
with Coumarin at high concentrations of drug. For Fe@Au Hydrogel, three loaded sam-
ples were dispersed in 3.5 ml after centrifugation as low drug concentration was used for
hydrogel loading. After comparing the results for the three conditions, it was decided
to perform the release at high temperature;low pH condition for all the three samples.
High Temperature;Low pH
Two loaded samples each for Fe@Au PEG and Fe@Au PEG Hydrogel were dispersed
in 3.5 ml MQ water after centrifugation for 20 minutes at 14,500 rpm. While for
Fe@Au Hydrogel, three loaded samples were dispersed in 3.5 ml water. At time tinitial,
three systems were measured using UV-vis. After that, pH was measured for all the three
systems (Fe@Au Hydrogel, Fe@Au PEG and Fe@Au PEG Hydrogel). For Fe@Au PEG,
Fe@Au Hydrogel and Fe@Au PEG Hydrogel normal pH values were 7.07, 7.04 and 7.02
respectively. To lower the pH, 0.25mM HCl was added to the these three systems. Final
pH values for Fe@Au PEG Fe@Au Hydrogel and Fe@Au PEG Hydrogel were 3.25, 3.22
and 3.16 respectively. Afterwards, these samples were measured in UV-Vis to observe
the effect of pH and record t0. These samples were then placed on the heating bath
at 40 oC with stirring at 500 rpm and measurements were performed using UV-Vis at
different time intervals.
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2.3.2 L-Dopa Release
L-dopa release was also studied at high temperature;low ph condition. Similar procedure
to Coumarin was used for L-dopa release but only single loaded sample for each system
was used for L-dopa release.
High Temperature Low pH
One sample each of Fe@Au PEG, Fe@Au Hydrogel and Fe@Au PEG Hydrogel systems
loaded with L-dopa was centrifuged at 14,500 rpm for 20 minutes. After centrifugation,
supernatant was removed and loaded NPs were dispersed in 3.5 ml MQ water. As with
Coumarin, tinitial was measured for these samples using UV-Vis. pH of these samples
was then measured using pH meter. Values of pH for Fe@Au PEG, Fe@Au Hydrogel and
Fe@Au PEG Hydrogel were found to be 6.97,7.12 and 7.01 respectively. 0.25mM HCl
was added to these samples to lower the pH. After HCL addition, pH for Fe@Au PEG,
Fe@Au Hydrogel and Fe@Au PEG Hydrogel were reduced to 3.50, 3.15 and 3.01 respec-
tively. Effect of pH was observed by measuring samples in UV-vis at time t0. These
samples were then placed on the heating bath at 40 oC and 500 rpm and change in the
absorbance values were observed with UV-Vis at different time intervals.
2.3.3 Cytochrome c
For Cytochrome C release studies procedure similar to Coumarin and L-dopa was
adopted. For cyt c two loaded samples each for Fe@Au PEG Fe@Au Hydrogel and
Fe@Au PEG Hydrogel were used for release study.
High Temperature Low pH
Fe@Au PEG, Fe@Au Hydrogel and Fe@Au PEG Hydrogel loaded with Cyt C (2 sam-
ples each for three systems) were centrifuged at 14,500 for 20 minutes. Supernatant was
removed from these centrifuged samples and 2 samples for each system (Fe@Au PEG,
Fe@Au Hydrogel and Fe@Au PEG Hydrogel) were dispersed in 3.5 ml MQ water sepa-
rately. These samples were than measured using UV-Vis to record tinitial. After measure-
ment, pH was measured for these samples using pH meter. Values of pH for Fe@Au PEG,
Fe@Au Hydrogel and Fe@Au PEG Hydrogel were recorded as 7.05, 7.01 and 7.10 respec-
tively. To make the solution acidic, 0.25mM HCl was added to these samples. After
HCl addition, pH for Fe@Au PEG, Fe@Au Hydrogel and Fe@Au PEG Hydrogel sam-
ples changed to 3.21, 3.4 and 3.15 respectively. Effect of pH was then observed by
measuring samples in the UV-Vis at time t0. After measurement, samples were placed
on the heating bath at 40 oC with stirring at 500 rpm to force the drug out of the NPs
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carrier. Changes in the absorbance values at different time intervals were recorded with
UV-Vis. Release study set up is shown in Figure 2.4.
Figure 2.4: Release setup for the study of drug release Fe@Au PEG, Fe@Au Hydrogel
and Fe@Au PEG Hydrogel loaded with Coumarin, L-dopa and Cytochrome c
2.4 Characterization techniques
2.4.1 DLS
Size distribution of NPs can be measured with DLS. Brownian motion of suspended
particles scatter light in different directions with varying intensities and degrees of polar-
ization after light interacts with particles in the solution[146, 147]. Intensity of scattered
light is being measured in this case. Kinetic energy of the particles can cause random
motion of particles. This random motion can change the intensity of scattered light with
time[148].
Dynamic light scattering measures the diffusion coefficient, size and distribution of par-
ticles in colloidal dispersions. Stokes-Einstein equation is used to estimate the hydrody-
namic diameter. Diffusion in a dilute dispersion is give as,
D =
kbT
6piηRh
(2.1)
In this equation kb is the Boltzmann constant, T is the absolute temperature in K, Rh
is the hydrodynamic radius and η is the intrinsic viscosity of the solvent[148].
Nano sizer is the instrument that was used to measure the hydrodynamic sizes of NPs.
It can measure size of the particles from lower than nanometers upto microns[149]. Zeta
Sizer, which measures both size and zeta potential is shown in Figure 2.5. Principle
used to measure samples by this instrument is also explained in Figure 2.5.
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2.4.2 Zeta Potential
Zeta potential was also measured using nano sizer. Zeta potential is the amount of
electrical charge at the electrical double layer formed by the charged particles. The
speed at which charged particles are moving under the influence of an electric field
is called electrophoretic mobility [150]. It is measured with the laser doppler micro-
electrophoresis which creates an electric field. Electrophoresis is then measured by using
phase analysis light scattering [151]. From electrophoretic mobility, zeta potential is
calculated using the Smoluchowski equation [152].
υE = 4pi0εr
ξ
6piµ
(1 + kr) (2.2)
where υE is the mobility of the particles in electric field, k is the Debye-Huckel parameter,
0 and εr are the relative dielectric constants and electrical permittivities of vacuum
respectively, r is the radius of the particle and µ is the viscosity of the solution [152].
Figure 2.5: Zeta sizer and principle of measurement respectively
Instrument was turned on with settings to measure both size and the zeta potential of
particles. Size was measured in the plastic size cuvette and zeta potential was measured
with zeta cuvette. The cuvettes used for the measurement are shown in Figure 2.6.
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Figure 2.6: Zeta and size cuvettes used for measurements
2.4.3 UV-vis Spectroscopy
The instrument is based on the absorption of light by particles in solution, it measures
the amount of ultraviolet or visible radiation which is absorbed by substance in solution.
Beer Lambert law is used to measure the concentration by using the absorption spectra
[153, 154].
A = −
(
I
I0
)
= ecl (2.3)
In this equation, A is the absorbance, I0 and I are the intensities of light before and
after the light passes through the sample, c is the concentration of solute in solution, l
is the path length of radiation through the sample. Absorbance is measured in UV-vis
at specific a wavelength. Normally, wavelength which gives maximum absorbance value
is chosen. Three different procedures are used to calculate the absorption. When it is
not easy to get a sample of reference substance, standard absorptivity value procedure is
used. Second procedure is single or double point standardization while third is calibra-
tion which is used when standard solution with known concentration is measured with
corresponding measurement of the absorbance [153]. One possible problem with this
instrument can be false positive results due to secondary binding or some nonspecific
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adsorption [95]. UV-24011PC, which was used for the measurements, is shown in the
Figure 2.7.
UV-vis was turned on and baseline with water was done before the measurements of
solutions. Cuvette used in the measurements is shown in Figure 2.8.
Figure 2.7: Uv-vis instrument used for the measurements
Figure 2.8: Cuvette used for the measurements UV-vis
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2.4.4 S(T)EM
Scanning transmission electron microscope (S(T)EM) is used for the characterization
of nanostructures. S(T)EM is a valuable instrument as it gives electronic structure of
single atoms with extreme sensitivity and information for the composition of various
elements. Working principle for the S(T)EM is based on scanning of the sample with
focussed beam of electrons, and collecting the desired signals to produce an image[155].
Working principle is similar to the SEM, the difference is the use of thin specimens
in S(T)EM. Thin specimens are used in S(T)EM to avail the transmission modes of
imaging. S(T)EM is a relatively fast means for characterizing nanostructures because
there is no need of grinding, polishing or ion milling[156].
Hitachi S-5500 S(T)EM instrument placed in NTNU nanolab was used to study the
samples. Samples were deposited on the C-coated copper TEM grids and placed on the
sample holder. This sample holder was then placed inside the instrument. Current and
voltage were adjusted to get the desired images and information for the samples.
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3.1 Synthesis and Characterization of Fe@Au NPs
Fe@Au NPs were synthesized by adding chloroauric acid in the hot citrate stabilized Fe
NPs solution. Size of the particles was measured using S(T)EM and DLS. Figure 3.1
a-e) shows a representative S(T)EM image of Fe@Au NPs, DLS sizes and zeta potential
values of Fe@Au NPs measured at 25 oC and 40 oC, effect of pH on the size and UV-vis
spectra of Fe@Au particles at 25 oC and 40 oC respectively. Error bars indicate standard
deviation from three measurements. S(T)EM measurement provides the average size of
Fe@Au NPs as 24±5 nm, while DLS gives an average size of 54.30± 0.52 nm. This
difference in the values is because DLS measurement gives the hydrodynamic diameter,
the diameter of the dispersed particles in the solution, while size measurement with
S(T)EM gives the dry diameter. Further, the difference lies in the fundamental principle
of measurement used in the two techniques.
Zeta potential depicts the stability of the Fe@Au NPs, a higher value indicates higher
stability. High negative zeta potential (-36.80±0.896 mV) of Fe@Au NPs confirms their
stability in aqueous medium. There is no substantial change in the zeta potential values
of the NPs on increasing temperature. This indicates that the particles are stable to
aggregation at higher temperatures. This stability is provided by the presence of citrate
ions on the surface of the NPs that generate Coulombic repulsion among NPs. However,
Figure 3.1 d) shows an increase in size of Fe@Au NPs when pH is decreased. This is
because of protonation of the citrate groups on Au surface which are formed at lower pH.
This results in reduced electrostatic stability leading to agglomeration of NPs. Figure
3.1 e) shows the absorbance peak for Fe@Au NPs at 25 oC and 40 oC respectively. LSPR
of these NPs is obtained around 524 nm and there is no relative shift of the peak at
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increased temperature. This, in addition to the size and zeta potential results, indicates
that the synthesized NPs are stable towards aggregation with respect to temperature.
Figure 3.1: a) Representative S(T)EM image of Fe@Au NPs b) Variation of DLS
sizes of Fe@Au NPs at 25 oC and 40 oC c) Variation of Zeta potential of Fe@Au NPs
at 25 oC and 40 oC d) Variation of DLS sizes of Fe@Au NPs with pH e) UV-vis spectra
of Fe@Au NPs at different temperatures
3.2 Coating of Hydrogel
As discussed in the method section 2.2.2, hydrogel samples A and B were used for the
coating of Fe@Au NPs. In the preceding section, the physico-chemical properties of both
hydrogels, which were used in this study, will be discussed.
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3.2.1 Physico-chemical properties of hydrogels
Both hydrogels A and B are pNIPAm/AAc based and were synthesized in Ugelstad
laboratory previously [157]. The basic difference between the two is the initial stabi-
lizer concentration (Sodium dodecyl sulphate, SDS)- high SDS concentration is used for
hydrogel B.
Hydrogel A Figure 3.2 a) and c) show the sizes and zeta potentials of hydrogel A
at 25 oC and 40 oC respectively. While 3.2 d) and e) represent the reversibility of the
hydrogel in terms of size and volumetric swelling ratios respectively (α). α is defined as
α =
(
DH
D0
)3
where DH = hydrodynamic diameter of the hydrogel at any temperature
(T oC) during heating/cooling and D0 = hydrodynamic diameter of the hydrogel at
room temperature (T oC) during heating/cooling. It is important to mention here that
α values were calculated separately for heating and cooling.
Hydrogel A shows a decrease in the size at higher temperature due to phase transition
behaviour, as discussed in section 1.3.3.3. PNIPAm based polymers undergo endother-
mic phase transition that is driven by entropy. This happens above VPTT, when the
hydrogels transit from hydrophilic to hydrophobic state. Figure 3.2 b) shows that de-
crease in pH causes collapse of the hydrogel owing to protonation of the carboxylic
groups from AAc blocks. Dissociated poly AAc segments are more hydrophilic than
non-dissociated segments, whereby a transition from lower to higher pH causes a de-
crease in the free energy of mixing [158]. Zeta potential for hydrogel A is -17.20±0.12
mV at 25 oC. Zeta potential decreases at higher temperature due to decrease in size
at elevated temperature, that leads to increase in the surface charge of the hydrogel.
Additionally, carboxyllic groups on the surface of hydrogels are more exposed at higher
temperature due to hydrophilic-hydrophobic transition above VPTT. As discussed in
section 1.3.3, hydrogel based systems can release the drug owing to environmentally
switch-able structures. Hydrogel A has shown substantial reversibility with respect to
temperature, as confirmed from Figure 3.2 c). VPTT values for heating and cooling
were calculated as 37.7 oC and 36.7 oC respectively (using developed procedure given
in Appendix E) which further confirm the reversible nature of this system . Volumetric
swelling ratios are better representations of the swelling of hydrogels owing to the fact
that the hydrogels swell or collapse volumetrically rather than as a single chains.
From the above discussion, it can be concluded that hydrogel A shows collapse at around
37.5 oC which confirms that it will change its structure at this temperature which is close
to body temperature. Increase in the value of zeta potential also indicates decrease in
the particle size and no substantial change in stability. Reversibility of the hydrogels
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is also confirmed from the volumetric swelling ratios with very minor difference in the
heating and cooling collapse temperatures which is very important for drug delivery
applications.
Figure 3.2: a) Variation of DLS sizes of hydrogel A at 25 oC and 40 oC b) Variation of
DLS sizes of hydrogel A with pH c) Variation of Zeta potentials of hydrogel A at 25 oC
and 40 oC d) Variation of sizes of hydrogel A as function of temperature e) Variation
of α as a function of temperature
Figure 3.3 a) and b) represents the STEM images for Hydrogel A at 25 oC and 50 oC
respectively. It can be observed from these images that at 25 oC, hydrogels are uniformly
distributed and at 50 oC they from aggregates. This might be due to the effect of drying
of nanogels from solution, because the nanogel solution was heated and then a drop of the
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heated solution was put on the STEM grid. Moreover, as it is confirmed from the DLS
measurements, that there is a decrease in the size of nanogels at higher temperature. It
is reasonable to state that DLS is measuring these nanogels individually rather than as
an aggregate owing to hydrophilic environment around each particle.
Figure 3.3: (a) Representative S(T)EM image of hydrogel A at 25 oC (b) Represen-
tative S(T)EM image of hydrogel A at 50 oC
Hydrogel B Figure 3.4 a) and c) show the sizes and zeta potentials of hydrogel A at
25 oC and 40 oC respectively, while Figures 3.4 d) and e) represent the reversibility of
the hydrogel in terms of size and volumetric swelling ratios respectively.
Size and zeta potential trend is similar to hydrogel A with smaller size of gels for hydro-
gel B, as in this case higher, stabilizer concentration is used compared to that of hydrogel
A. Lower values for zeta potential (-12.3 mV±0.55) are also observed for this hydrogel
compared to hydrogel A. Reversibility of the hydrogel B is confirmed as indicated in the
Figure 3.4 c. However, hysteresis is observed while cooling down the hydrogels, it not
very significant due to the fact that different size values were observed while measuring
the same sample twice. Volumetric swelling ratio values also indicate small hysteresis
when cooling down. Hydrogel B has better reversibility with not very significant hys-
teresis as compared to hydrogel A. This is also confirmed from the VPTT calculations
for heating and cooling of hydrogel B. For heating and cooling, collapse temperature is
38 oC for this hydrogel, which indicates reversibility of this nanogel.
For hydrogel B, similar results were observed as with hydrogel A in regards to collapse
and reversibility. However, hydrogel B is smaller in size and also shows better reversibil-
ity under heating and cooling than hydrogel A as confirmed from VPTT calculations.
S(T)EM images for hydrogel B (not shown here) indicate similar behaviour as shown by
hydrogel A.
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Figure 3.4: a) Variation of DLS sizes of hydrogel B at 25 oC and 40 oC b) Variation of
DLS sizes of hydrogel B with pH c) Variation of Zeta potentials of hydrogel B at 25 oC
and 40 oC d) Variation of sizes of hydrogel B as function of temperature e) Variation
of α as a function of temperature
3.2.2 Fe@Au Hydrogel A
Method 1 As explained in section 2.2.2, Fe@Au NPs were coated with hydrogel A and
B by using two different methods. Coating of Fe@Au NPs with hydrogel A by method 1
shows opposite trend for size, zeta potential, reversibility and volumetric swelling ratio
values compared to only hydrogel A as shown in the Figure3.5. Figure3.5 a-d) illustrate
the size, zeta potential at 25 oC and 40 oC and reversibility, volumetric swelling ratios
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for Fe@Au Hydrogel A respectively. Figure 3.5 a) indicates increase in size at 40 oC
for Fe@Au Hydrogel compared to size at 25 oC. This increase in size with increasing
temperature might be due to the effect of Fe@Au NPs acting as a cross-linker whereby
pulling together the gel units. This hypothesis is also supported by the STEM images for
this system at 25 oC and 50 oC (Figure 3.6). Studies with similar systems also support
this assumption [159].
High negative values for zeta potential indicate that coating of hydrogel provides further
stability to the Fe@Au NPs as illustrated by Figure 3.5 c), which is significant in drug
loading application. Figure 3.5 f) shows that due to higher charge on the surface of
Fe@Au NPs, zeta potential of Fe@Au Hydrogel has larger negative value (zeta potential
-34.40±0.42 mV) compared to the hydrogel (zeta potential -17.2±0.12 mV) .The increase
in zeta potential of Fe@Au Hydrogel at higher temperature might be due to increase
in the size which ultimately decreases the average charge per unit area of the particles.
Reversibility of the Fe@Au Hydrogel system is confirmed as indicated in Figure 3.5 c).
Opposite trend is observed but reversibility of the coated gels provides a platform for
their use in drug delivery applications. Hysteresis is not very large and can be explained
on the same grounds as with hydrogels. Volumetric swelling ratios also confirms the
reversibility of these systems with some hysteresis between 35 oC to 40 oC which is not
very significant and can be due to cooling and heating effects and error stemming from
repeated measurements. VPTT values for this system are around 38.5 oC and 37.8 oC for
heating and cooling respectively. which confirm that these systems are quite reversible
even after addition of Fe@Au to the system. This indicates that coating does not have
significant effect on the reversibility of the nanogels, although bare hydrogels are more
reversible in terms of swelling-collapse behaviour.
UV-vis spectra of Fe@Au Hydrogel type A shows their absorbance peak around 518
nm compared to the Fe@Au which shows peak at 524 nm. This shift in the peak
can be explained on the basis of increase in the energy required to exit the electron
which shifts the wavelength to lower value as explained by Planks equation (E=hc/λ).
This behaviour is shown due to the coating of hydrogel on Fe@Au NPs. This further
confirms that hydrogel coating does affect the optical signature of the Fe@Au but the
peak is still visible. Moreover, at higher temperature, there is not any significant shift
in the wavelength for Fe@Au Hydrogel system. The minor difference at 25 oC and 40
oC is attributed to the turbidity of the hydrogels at elevated temperatures.
From the above discussion, it is inferred that Fe@Au Hydrogel type A shows increase
in size at higher temperature but comes back to almost the same size as indicated
by reversibility data. Moreover higher stability of the Fe@Au NPs is achieved by their
coating with the polymer with minor effects on the optical properties of the Fe@Au after
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coating with polymer as indicated by UV-vis absorbance peak. Therefore, Fe@Au coated
with hydrogel can act as a unique drug carrier with magnetic, optical and switchable
payload release signatures. Figure 3.5 f) shows a comparsion of zeta potential of Fe@Au,
hydrogel A and and Fe@Au Hydrogel A as a function of temperature. Stability of Fe@Au
NPs after coating is retained (high negative values of zeta potential for both Fe@Au and
Fe@Au Hydrogel A), while the hydrogel stablity should not be directly interpreted from
the data since size changes also affect zeta potential values.
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Figure 3.5: a) Variation of DLS sizes of Fe@Au Hydrogel A coated by method 1 at 25
oC and 40 oC b) Variation of Zeta potential of Fe@Au Hydrogel A coated by method
1 at 25 oC and 40 oC c) Variation of sizes of Fe@Au Hydrogel A network coated by
method 1 as a function of temperature d) Variation of α as a function of temperature
e) UV-vis spectra of Fe@Au Hydrogel A coated by method 1 at 25 oC and 40 oC f)
Comparison of zeta potentials of Fe@Au, hydrogel A and and Fe@Au Hydrogel A at
25 oC and 40 oC
S(T)EM images for Fe@Au Hydrogel A are shown in the Figure 3.6 a) and b). These
images confirmed the presence of Fe@Au on the periphery of the nanogel surface which
means that enough space is available on the surface of the hydrogels for drug loading.
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This indicates that drug will have sufficient chances to interact with the hydrogel struc-
ture as well as magnetic and optical properties are provided by the Fe@Au NPs present
on the surface of the hydrogel. Moreover, heating of this system at 50 oC will cause
the aggregation of the hydrogel as also shown by hydrogel sample alone. Interesting
point here is that NPs are still on the surface of the hydrogels and acting as a cross-
linker and pulling the gel structures together. Another interesting observation is the
increase in particle number density upon heating, hinting towards collapse of individual
hydrogel units. However, DLS data provide increase in sizes which can be attributed to
cross-linking effect of NPs acting as bridge molecules between collapsed hydrogel units.
Figure 3.6: a) Representative S(T)EM image of Fe@Au Hydrogel A coated by method
1 at 25 oC b) Representative S(T)EM image of Fe@Au Hydrogel A coated by method
1 at 50 oC
Method 2 Similar set of studies were performed for coating of hydrogel type A by
method 2 and more or less similar outcomes were obtained. These results for size, pH
effect, zeta potential, swelling de-swelling and volumetric swelling ratios are depicted
in Figure 3.7 a-e) while figure f) presents the UV-Vis spectra. Size and Zeta poten-
tial measurements shows similar results as for Fe@Au Hydrogel A coated with method
1. Reversibility studies for Fe@Au Hydrogel A coated with method 2 shows higher re-
versibility with VPTT of around 37.9 oC and 37.7 oC for heating and cooling respectively.
Low hysteresis is indicated by the Figure 3.7 d) and e) compared to the Fe@Au Hydrogel
A coated by method 1. This observation made Fe@Au Hydrogel A coated with method
2 a better method for coating of Fe@Au NPs. Fe@Au optical signature after coating
is also valid for this method. Method 1 and 2 almost provide similar sets of results.
However Fe@Au Hydrogel type A coated by method 2 gave better reversibility of the
Fe@Au Hydrogel as confirmed by VPTT calculations for heating and cooling and also
they gave higher loading efficiency, which will be discussed in the loading section. On
the basis of these superior qualities of Fe@Au Hydrogel coated with method 2, it was
decided to use it for the loading and release studies in this research.
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Figure 3.7: a) Variation of DLS sizes of Fe@Au Hydrogel A coated by method 2 at
25 oC and 40 oC b) Variation of DLS sizes of Fe@Au Hydrogel A coated by method 2
with pH c) Variation of Zeta potential of Fe@Au Hydrogel A coated by method 2 at 25
oC and 40 oC d)Variation of sizes of Fe@Au Hydrogel A network coated by method 2
as a function of temperature e) Variation of α as a function of temperature f) UV-vis
spectra of Fe@Au Hydrogel A coated by method 2 at at 25 oC and 40 oC
S(T)EM images for the Fe@Au Hydrogel A coated with method 2 are represented in the
Figure 3.8 a) and b). Similar behaviour to method 1 can be observed for this method
as well. Presence of Fe@Au on nanogel surface before and after heating confirms the
coating with hydrogel A and also reduction in the size of hydrogels is clear from these
images.
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Figure 3.8: a) Representative S(T)EM image of Fe@Au Hydrogel A coated by method
2 at 25 oC b) Representative S(T)EM image of Fe@Au Hydrogel A coated by method
2 at 50 oC
3.2.3 Fe@Au Hydrogel Type B
Fe@Au Hydrogel B was used to compare it with the hydrogel A. Method 2 was used for
type B as it was concluded in the above section that method 2 provides better results
compared to that of method 1.
Method 2 Sizes, pH effect on size, Zeta potentials, reversibility and volumetric swelling
ratios for heating and cooling of Fe@Au Hydrogel B coated by method 2 are illustrated
in the Figure3.9 a-d) respectively.
Size measurements show increase in size of the hydrogel type B at higher temperature as
indicated for the hydrogel type A. Zeta potential of hydrogel has showed higher negative
values compared to type A which is advantageous in terms of stability and increase in
temperature does not induce large changes in zeta potential values for Fe@Au Hydrogel
B. Reversibility results indicate that Fe@Au Hydrogel type B system is appreciably
reversible with VPTT for heating and cooling at 39.8 oC and 39.5 oC respectively and
negligible hysteresis.
Better results for reversibility of the Fe@Au Hydrogel type B coated by method 2 as
well as higher loading values as show in the loading section and higher stability of this
system are the reasons for their use in this work.
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Figure 3.9: a) Variation of DLS sizes of Fe@Au Hydrogel B coated by method 2 at
25 oC and 40 oC b) Variation of DLS sizes of Fe@Au Hydrogel B coated by method 2
with pH c) Variation of Zeta potential of Fe@Au Hydrogel B coated by method 2 at 25
oC and 40 oC d) Variation of sizes of Fe@Au Hydrogel B network coated by method 2
as a function of temperature e) Variation of α as a function of temperature f) UV-vis
spectra of Fe@Au Hydrogel B coated by method 2 at at 25 oC and 40 oC
3.3 Fe@Au PEG
Coating of PEG is done on Fe@Au NPs because of several advantages of PEG coating
that includes increase in the half-life time of nanocarriers, through cloaking properties
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and steric stabilization. Size and zeta potentials of Fe@Au and Fe@Au PEG are illus-
trated in the Figures 3.10 a) and c). It is clear from the Figure 3.10 a) that there is
an increase in the size of Fe@Au to 74.81±2.18 nm after they are functionalized with
the PEG. S(T)EM images Figure 3.10 d) and e) also illustrate the increase in the size
after coating of PEG on Fe@Au. Figure 3.10 b) shows the effect of pH on the size of
Fe@Au PEG.
Increase in DLS size of Fe@Au PEG to 74.9±2.18 nm is similar to the previous study
done at uglestad laboratory [145]. Increase in the size is due to hydrophobic effect of PEG
at higher temperature that cause hydrphobic aggregation of NPs. This is also supported
by the S(T)EM images Figure 3.10 d) and e). Zeta potential of Fe@Au PEG NPs is -
31.30±2.68 mV compared to Fe@Au -36.80±0.90 mV. The difference is attributed to the
increase in the size after PEG coating. Furthermore, there is shift in the zeta potential
towards zero at higher temperature also due to slight increase in the size of Fe@Au NPs
at higher temperature.
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Figure 3.10: a) Variation of DLS sizes of Fe@Au PEG at 25 oC and 40 oC b) Variation
of DLS sizes of Fe@Au PEG with pH c) Variation of Zeta potential of Fe@Au PEG at
25 oC and 40 oC d) Representative S(T)EM image of Fe@Au at 25 oC e) Representative
S(T)EM image of Fe@Au PEG at 50 oC
UV-Vis Study PEG coating causes a red shift in the absorbance peak (529 nm) for
Fe@Au NPs as shown in the Figure 3.11 a) and b), this bathochromic shift caused by
the PEG coating is an indication of the increase in the size of NP after coating. This is
predicted by Mie-Drude theory [159]. This behaviour is observed at both 25 oC (Figure
3.11 a)) and 40 oC (Figure 3.11 b)) and is in conformation with previous studies [145].
Effect of temperature on Fe@Au PEG is not very significant even at low concentration,
which is important for the drug delivery application of this system and also for release
of the drug for this kind of carrier that depends on optical signature.
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Figure 3.11: a) UV-vis spectra of Fe@Au and Fe@Au PEG at 25 oC b) UV-vis spectra
of Fe@Au and Fe@Au PEG at 40 oC c) UV-vis spectra of Fe@Au PEG at 25 oC and
40 oC d) UV-vis spectra of Fe@Au PEG (low concentration) at 25 oC and 40 oC
3.4 Fe@Au PEG Hydrogel
Fe@Au NPs were coated with PEG and hydrogel. This system shows properties closer
to Fe@Au PEG. Thus these advanced nano-carriers can be significant in the drug de-
livery due to combined effect of PEG and hydrogel. Combination of PEG and hydrogel
showed very promising reversibility. Fe@Au PEG Hydrogel also show good stability as
illustrated by the zeta potential measurements. Figure 3.12 a-e) represent the size and
zeta potential at 25 oC and 40 oC, effect of pH on size, temperature induced reversibility
and reversibility based on volumetric swelling ratio values for this system.
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Figure 3.12: a) Variation of DLS sizes of Fe@Au PEG Hydrogel at 25 oC and
40 oC b) Variation of DLS sizes of Fe@Au PEG Hydrogel with pH c) Variation of
Zeta potential of Fe@Au PEG Hydrogel at 25 oC and 40 oC d) Variation of sizes of
Fe@Au PEG Hydrogel network as a function of temperature e) Variation of α as a
function of temperature f) UV-vis spectra of Fe@Au PEG Hydrogel at 25 oC and 40
oC
Size of Fe@Au PEG Hydrogel is around 163.9±2.36 nm at 25 oC, larger size of them
compared to Fe@Au Hydrogel and Fe@Au PEG is due to coating of both PEG and
Hydrogel. It also indicates that outer layer is formed by hydrogel and not PEG owing to
order of coating. Reversibility of this system is very promising and it also indicates that
outer layer is of hydrogel. Zeta potential value for this carrier is -32.40±0.40 mV and
effect of temperature is not very pronounced as illustrated in Figure 3.12. VPTT values
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for heating and cooling of this system are reported as 37.1 oC and 36.7 oC which are
less compared to Hydrogel and Fe@Au Hydrogel, due to incorporation of PEG which
induce hydrophobic effects at higher temperature.
Figure 3.13 a) and b) represents the ST(E)M images for Fe@Au PEG Hydrogel at 25
oC and 50 oC. It is clear from these images that Fe@Au NPs are present on the periph-
ery of the PEG-Hydrogel surface. As with hydrogel and PEG, this system also shows
aggregation at higher temperature, which may be due to drying, while in essence, the
collapsed hydrogel particles are being gelled together by Fe@Au NP units.
Figure 3.13: a) Representative S(T)EM image of Fe@Au PEG Hydrogel at 25 oC b)
Representative S(T)EM image of Fe@Au PEG Hydrogel at 50 oC
Three systems Fe@Au Hydrogel, Fe@Au PEG and Fe@Au PEG Hydrogel which were
discussed in the previous sections were used to study the loading of three drugs L-dopa,
Coumarin and Cytochrome c. Loading and encapsulation efficiencies results of these
system show their effectiveness in drug delivery applications.
3.5 Loading and Encapsulation Efficiencies
Loading and encapsulation efficiency confirms that these systems have potential to be
used as a drug carrier with promising results. Loading efficiencies were calculated by
using calibration curves given in Appendix B for three drugs.
3.5.1 L-DOPA
Loading results illustrated in figure3.14 a) and b) confirm that, method 2 and sample
type B give more promising loading compared to method 1 and sample type A.
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Figure 3.14: a) Loading efficiency Fe@Au Hydrogel A coated by method 1 and 2
b) Loading efficiency Fe@Au Hydrogel A coated by method 2 and Fe@Au Hydrogel B
coated by method 2
Optimized results for loading and encapsulation of L-dopa on three systems defined
above are depicted in Figure 3.15 a) and b). Loading efficiencies for Fe@Au PEG,
Fe@Au Hydrogel and Fe@Au PEG Hydrogel were 8.57 %, 10.20 % and 8.00 % respec-
tively. Loading of L-dopa on Fe@Au PEG might occur due to the interaction between
the methyl group on the L-dopa and the hydroxyl group on the PEG surface, they can
from strong bonds as methyl groups prefer to interact with the hydroxyl groups. L-dopa
concentration which gave maximum loading on Fe@Au PEG was 3 mg/ml while the NP
concentration was 2.50 mg/ml. Hydrophilic nature of PEG might be the reason for the
high values of the loading at high drug concentration.
In case of Fe@Au Hydrogel, hydrogen bonding between the carboxylic groups on the
hydrogel and hydroxyl groups on the L-dopa surface can be responsible for the loading
of L-dopa on the surface of the Fe@Au Hydrogel. It is also possible that hydroxyl
and/or amide groups on the surface of L-dopa attach with the acrylic acid present in
the hydrogel structure. This interaction can form strong bonds between the drug and
Fe@Au Hydrogel and provide high loading efficiencies. One of these interactions or
combination of these can be responsible for the loading of L-dopa on Fe@Au Hydrogel.
In this case, high loading is achieved at high NP concentration for Fe@Au Hydrogel and
low drug concentration.
It is more likely that in case of Fe@Au PEG Hydrogel, L-dopa is attached to the hydrogel
compared to the PEG because in Fe@Au PEG Hydrogel system, it is assumed that
hydrogel is on the surface, so drug has more chances to attach with hydrogel. However,
it might be possible that drug enters into the polymer structure and can reach the
PEG surface. If this might happen then release of the drug from this system might be
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slow. For this system, highest loading is achieved for high drug concentration as with
Fe@Au PEG.
Figure 3.15 b) shows the encapsulation efficiencies of the L-dopa on the Fe@Au PEG,
Fe@Au Hydrogel and Fe@Au PEG Hydrogel. It is clear from the Figure that encap-
sulation is high for the Fe@Au PEG and Fe@Au PEG Hydrogel because in these sys-
tems higher drug concentration were used. Low values of encapsulation efficiency for
Fe@Au Hydrogel were obtained due to low concentration of the drug which was used
for this particular system.
Figure 3.15: a) Loading efficiencies of Fe@Au Hydrogel, Fe@Au PEG and
Fe@Au PEG Hydrogel b) Encapsulation efficiencies of Fe@Au Hydrogel, Fe@Au PEG
and Fe@Au PEG Hydrogel
3.5.2 Coumarin
Coumarin loading was performed on the basis of results obtained from L-dopa loading
studies. NP concentrations used for Fe@Au PEG, Fe@Au Hydrogel and Fe@Au PEG Hydrogel
were similar to the ones used for loading studies of L-dopa. Drug concentration for
Coumarin was calculated based on the drug concentration used for L-dopa. Loading
efficiencies of coumarin on Fe@Au PEG, Fe@Au Hydrogel and Fe@Au PEG Hydrogel
were obtained to be 12.02 %, 8.25 % and 12.10 % respectively as shown in the Figure
3.16 a).
Loading of Coumarin on Fe@Au PEG is possibly due to the interaction between the
charged groups on the coumarin surface. One end of the PEG is anchored with the
Fe@Au, because thiol has strong affinity for the Au surface, while the other end on the
PEG surface is available to interact with the drug molecule. It is assumed here that
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one end of the PEG is attached with the bulky groups of the coumarin most probably
-NH group which is the positive center on the PEG surface. Molecular weight of the
Coumarin is 146.14 g/mol. It can be assumed that coumarin molecule goes further inside
the polymer structure, or else it can stay on the polymer surface due to hydrophobic
nature of the drug molecule.
In case of loading of Coumarin on hydrogel, it can be hypothesized that the interaction
between the electron donating coumarin structure and positive center on the hydrogel
surface is responsible for the loading. Coumarin is more hydrophobic in nature compared
to L-dopa and Cyt c due to the presence of the bulky groups, which are not very soluble in
water. Therefore in case of loading of coumarin on hydrogel, it can be assumed that the
loading is due to the hydrophobic interactions between the drug molecule and nanogel.
Drug molecules can be located on the surface of the hydrogel or may be squeezed into
the hydrogel surface.
Loading of the Coumarin on the surface of the Fe@Au PEG Hydrogel might be due to
the hydrophobic interaction as hydrogel is forming the outer layer in the Fe@Au PEG Hydrogel
system. It is also possible that the drug goes further inside the polymer structure and
interacts with the PEG. High loading efficiency indicates that more drug is loaded on
the surface of the Fe@Au PEG Hydrogel compared to Fe@Au Hydrogel due to combined
effect of nanogel and PEG.
Encapsulation efficiencies for the three systems are depicted in the Figure 3.16 b).
Fe@Au Hydrogel system has lowest encapsulation efficiency due to the fact that low
initial drug concentration was used for this particular system, while in case of the
Fe@Au PEG and Fe@Au PEG Hydrogel, higher values are indications of high initial
drug concentrations. Highest value for the Fe@Au PEG is because of low NPs concen-
tration for this system, which ultimately increases the ratio of amount of drug loaded
to the amount of NPs.
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Figure 3.16: a) Loading efficiencies of Fe@Au Hydrogel, Fe@Au PEG and
Fe@Au PEG Hydrogel b) Encapsulation efficiencies of Fe@Au Hydrogel, Fe@Au PEG
and Fe@Au PEG Hydrogel
3.5.3 Cytochrome - C (Cyt-C)
Cyt c shows highest loading for Fe@Au-Hydrogel and Fe@Au-PEG-Hydrogel. Cyt c
is a small water soluble heme protien having molecular weight of around 12,370 Da.
Hydrodynamic diameter of the Cyt c is around 3.5 nm (1.75 Rh measured with DLS).
This macromoleucle has a positive charge at pH 7. Studies with similar systems by
Smith et al. show that positive charge of the cyt c is responsible for his electrostatic
interaction with the negatively charged surface in the hydrogel structure. At neutral
pH, this protien has a net charge of +9.3 C, that is why there is a formation of polymer-
protien complex due to Coulombic forces between the hydrogel and the cyt c. Net
gain in the free energy due to effect of increased entropy through counterion release is
responsible for the formation of this cross-linked polyelectrolytes-protien complex. This
complex formation is the reason of higher loading efficiency for the Fe@Au-Hydrogel and
Fe@Au-PEG-Hydrogel systems. As the hydrodynamic diameter of the protein is around
3.5 nm, so it might be possible that protein diffuses into the polymer surface and goes
further inside the hydrogels [160].
Lower values of loading efficiency at higher drug concentration for Fe@Au-Hydrogel and
Fe@Au-PEG-Hydrogel might be due to less access of the polymer to the interior of the
protein and interaction between the protein and the NPs are not very significant.
While in case of the PEG, lower value of loading efficiency is attributed to hydrophilic
nature of both PEG and the protein, so it might be difficult to bind more protein to the
surface of the PEG. When protein is attached with the PEG surface, there is a repulsive
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force between the PEG and the protein, as PEG chains lose their conformational entropy
and available volume for each polymer molecule is then decreased. Moreover, available
conformations for the PEG molecules decrease because of their compression owing to
osmotic repulsive force generated due to protein chains[161]. Increase in drug loading
at higher drug concentration is possibly because of the hydrophillic nature of the PEG,
so that when drug concentration is increased, chances of collision between the drug
and the PEG are also increased. Figure 3.17 a) and c) shows the loading efficiencies
of 0.1 mg/ml and 0.5 mg/ml Cyt c on Fe@Au Hydrogel, Fe@Au PEG Hydrogel and
Fe@Au PEG systems.
Figure 3.17: a) Loading efficiencies of Fe@Au Hydrogel, Fe@Au PEG and
Fe@Au PEG Hydrogel at low drug concentration b) Encapsulation efficiencies of
Fe@Au Hydrogel, Fe@Au PEG and Fe@Au PEG Hydrogel at low drug concentration c)
Loading efficiencies of Fe@Au Hydrogel, Fe@Au PEG and Fe@Au PEG Hydrogel high
drug concentration d) Encapsulation efficiencies of Fe@Au Hydrogel, Fe@Au PEG and
Fe@Au PEG Hydrogel high drug concentration
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Encapsulation efficiency values are indicated in the Figure 3.17 b) and d) for 0.1 mg/ml
and 0.5 mg/ml Cyt c respectively. It is clear form the graphs that as the drug concen-
tration is increased more drug is encapsulated to the NPs.
3.6 Release
Section 1.14 indicates the different factor which govern release of the drug from the
nanocarriers. Release study of the three drugs used for the loading studies is done at
low-pH (3.5) and high temperature ( 40 oC). This condition is used because previous
work done with the similar systems provide highest release for this particular condition.
[157, 162]. Release (%) calculations are given in the Appendix D.
3.6.1 Coumarin
Release kinetics for the Coumarin for three systems are shown in the Figure 3.18. For
Fe@Au Hydrogel, Fe@Au PEG and Fe@Au PEG Hydrogel systems, release of Coumarin
was very unstable and the values were very fluctuating. This is due to the hydrophobic
nature of Coumarin and it might not be possible to study the release of this drug
by the technique used in this studies (temporal UV-vis study of the NPs and release
medium, without separating the particles from free drug). As indicated in Figure 3.18
for Fe@Au Hydrogel there was a release of about 18.23% in 1 hour, and after 2.03 hours
it increased to 46.26%. However, after 3.05 hour there is a decrease in the drug release
to 12.10% and increase to 80.78% after 5.03 hours. This is very unusual drug release
which indicates that interactions between the drug and the Fe@Au Hydrogel is very
complex and it is suggested that different release setup should be used for Coumarin
release. It might be possible to get efficient results by loading the drug to the carriers
at high temperature and afterwards study the release at lower or normal temperature.
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Figure 3.18: Release percentage of Drug (Coumarin) from Fe@Au Hydrogel,
Fe@Au PEG and Fe@Au PEG Hydrogel systems
Similar results were observed for the Fe@Au PEG, Fe@Au PEG Hydrogel.
Hence, it is concluded that for Coumarin release form these particular systems, different
approach should be used to estimate the release. Additionally, the problems faced during
the studies of improper mixing might cause the fluctuated increase and decrease release
rates. It is also possible that interaction of the drug with the carriers is such that
after changing pH and temperature, there is burst release of the Coumarin during the
initial phase of the release, and in the final phase the drug which was located inside
the polymeric structure is released at a non-uniform rate. Due to hydrophobic nature
of Coumarin, it might be possible that the released drug still remains associated with
the hydrophobic (due to increased temperature) hydrogels even after release. Since this
drug does not go out into the release medium where the drug concentration is being
analysed, random fluctuations in the release percentage are being observed.
3.6.2 L-DOPA
Similar condition was employed for the release of L-dopa from the Fe@Au PEG, Fe@Au Hydrogel
and Fe@Au PEG Hydrogel systems.
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Figure 3.19: Release percentage of Drug (L-dopa) from Fe@Au Hydrogel,
Fe@Au PEG and Fe@Au PEG Hydrogel systems
Promising results were observed in case of release of the L-dopa form the Fe@Au PEG,
Fe@Au Hydrogel and Fe@Au PEG Hydrogel systems as illustrated in the Figure 3.19.
It is important to mention here that due to the initial problem with the stability of
the particles as the pH was reduced by adding 0.25mM HCl to the loaded NPs, t 0
is used which is after 2 to 3 hours from the start. For Fe@Au Hydrogel loaded with
L-dopa 37.20% release of the drug was observed after 0.97 hours. While it increased to
44.51% and 66.07% after 5 and 10 hours respectively. While there is a slight decrease
in the release rate after 13.05 and 18.07 hours. This behaviour was observed because
of the improper mixing of the Fe@Au Hydrogel loaded with L-dopa drug system as it
was observed during the experiment that NPs are attaching with the magnetic stirrer.
Sonication of the sample was done at regular intervals to minimize this effect, which
ultimately enhanced the release to 75.61% after 22.67 hours as indicated in the Figure
3.19. After 31.20 hours, 87.20% drug was released from this system. Previous study
done with the similar systems during project work [162] gave almost similar results ( 83%
release), which indicates that these results are reproducible and reliable.
Fe@Au PEG loaded with L-dopa also showed promising results. It can be observed that
there is a bit slow release from this system compared to the Fe@Au Hydrogel owing to
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the fact that hydrogel is sensitive to changes in pH and temperature compared to the
PEG. For this system 8.98% release was observed after 2.18 hours, while it decreased
to 6.27 % after 4.03 hours owing to the same fact of improper mixing as with L-dopa.
However, there is a slow increase from 17.70 % after 6.13 hours to 22.87 % in 4.27 hours.
Same pattern is shown until 37.69% drug was released after 48.58 hours. After 59.08
hours, 55.93 % drug was released from Fe@Au PEG. Lower values compared to hydrogel
system indicate that drug release from hydrogel system is due to change in its structure
with changes in pH and temperature.
Drug release from Fe@Au PEG Hydrogel systems show similar trend of slow drug release
as with PEG system as illustrated in the figure. After 3.12, hours 9.37 % drug was
released which increased to 19.41% after 13.35 hours. Fluctuation in values is attributed
to similar reasoning of improper mixing. Drug release further increased to 21.98% after
17.25 hours, ultimately reaching a value of 28.98% after 52.93 hours. Lower release
percentage from this system is due to fact that coating of both PEG and hydrogel
increase the size of the carrier, and it is possible that drug is entrapped at different
layers of PEG and hydrogel structure so it required more time to release.
3.6.3 Cytochrome-C
Cytochrome c release kinetics from the Fe@Au PEG, Fe@Au Hydrogel and Fe@Au PEG Hydrogel
systems are illustrated in Figure 3.20. It can be observed from the figure that drug re-
lease profile for this system is very promising and gives very uniform release of the drug.
It is necessary to mention here that, the release percentage for cytochrome c is calcu-
lated based on the bound cyt c with the NPs. Since it is assumed that cyt c is bound
to the polymer and UV-Vis is providing the peak for the bound cyt c with the polymer,
decrease in absorbance values for the drug was observed, unlike in case of L-dopa
Fe@Au Hydrogel loaded with cyt c shows constant release of the drug, 28.3% drug is
released after 1.60 hours. As shown in the graph, drug release from this system was
uniform and increased at a constant rate. After 7.65 hours, 35.4% drug was released
from the Fe@Au Hydrogel. While after 15.85 hours, there was 41.9% release of the drug
from the initial value, however there was a minor decrease in the drug release percentage
that can be attributed to the same reason as with drug release from the L-dopa and
Coumarin systems. After 43.42 hours, there was 55.4% drug release from this system.
Drug release from the Fe@Au PEG was faster compared to the Fe@Au Hydrogel. This
might be due to the lower loading efficiency for this system. Also, PEG is hydrophilic
therefore, it does not interact very effectively with proteins. After 2.65 hours, there
was drug release of 63.2 % while the decrease in the drug release at some time points
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indicated the effect of improper mixing. It can be seen from the graph that after 12.10
hours, there was release of 85.9 % which ultimately increases to 89.1 % after 43.40 hours.
In case of the Fe@Au PEG Hydrogel, similar trend of constant and relatively slow drug
release was observed as with Fe@Au Hydrogel after release of 30 % in 0.55 hours. 39.6
% drug release occured form this system after 7.52 hours. This drug release percentage
increased to 43.6 % after the 15.48 hours. The drug release from Fe@Au PEG Hydrogel
is not very fast and it slows down. After 33.72 hours there was drug release of 49 %
which increase to 50.8 % after 47.73 hours which indicates that there is a slow release
of the drug from this system. This might be due to the increase in the structure of the
Fe@Au PEG Hydrogel as this structure has layers of hydrogel as well as PEG, so drug
takes more time to release.
Figure 3.20: Release percentage of Drug (Cytochrome-C) from Fe@Au Hydrogel,
Fe@Au PEG and Fe@Au PEG Hydrogel systems
3.6.4 Model-Fitting
Fitting of release data was done by using kinetic models. Four different models zero or-
der, first order, Higuchi and power law were used to estimate the behaviour of Cyt c and
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L-dopa release kinetics from Fe@Au PEG, Fe@Au Hydrogel and Fe@Au PEG Hydrogel
systems [142, 163].
3.6.4.1 L-dopa Fe@Au Hydrogel
Figure 3.21 a-d) illustrate the models zero order, first order, Higuchi, and power law
respectively for L-dopa release kinetics from Fe@Au Hydrogel. Power law model provides
the value for n (diffusional exponent for Peppas equation). By examining values for zero
order , first order, and Huguichi model fit shown in the graphs a, b and c it is clear that
for this system zero order model provides the best linear fit with rate constant of k =
0.0321 hour−1.
Figure 3.21: a) Model Fitting of L-dopa Fe@Au Hydrogel using zero order model
b) Model Fitting of L-dopa Fe@Au Hydrogel using first order model c) Model Fit-
ting of L-dopa Fe@Au Hydrogel using Higuchi model d) Model Fitting of L-dopa
Fe@Au Hydrogel using power law model
3.6.4.2 L-dopa Fe@Au PEG
Figure 3.22 a-d) illustrate the models zero order, first order, Higuchi, and power law
respectively for L-dopa release from Fe@Au PEG. For this system first order model
gives the best linear fit having rate constant k = 0.0361 hour−1.
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Figure 3.22: a) Model Fitting of L-dopa Fe@Au PEG using zero order model b)
Model Fitting of L-dopa Fe@Au PEG using first order model c) Model Fitting of L-
dopa Fe@Au PEG using Higuchi model d) Model Fitting of L-dopa Fe@Au PEG using
power law model
3.6.4.3 L-dopa Fe@Au PEG Hydrogel
Release kinetics for L-dopa from Fe@Au PEG Hydrogel is depicted in the Figure 3.23
for the four models used. It is clear from the figure that first order model gives the best
linear fit for l-dopa release from the Fe@Au PEG Hydrogel. rate constant estimated by
using this model give value of k = 0.0546 hour−1.
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Figure 3.23: a) Model Fitting of L-dopa Fe@Au PEG Hydrogel using zero order
model b) Model Fitting of L-dopa Fe@Au PEG Hydrogel using first order model c)
Model Fitting of L-dopa Fe@Au PEG Hydrogel using Higuchi model d) Model Fitting
of Fe@Au PEG Hydrogel using power law model
3.6.4.4 Cytochrome - C Fe@Au Hydrogel
Models used for L-dopa release from Fe@Au Hydrogel, Fe@Au PEG, and Fe@Au PEG Hydrogel
systems also used for the release of cyt c from these systems. Figure depicts 3.24 the
release kinetics of cyt c from Fe@Au Hydrogel using four different models. It can be
concluded form the Figures that zero order model provides the better linear fit compared
to first order and higuchi model. Value of rate constant K = 0.0232 hour−1 is estimated
from zero order model.
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Figure 3.24: a) Model Fitting of Cytochrome - C Fe@Au Hydrogel using zero order
model b) Model Fitting of Cytochrome - C Fe@Au Hydrogel using first order model
c) Model Fitting of Cytochrome - C Fe@Au Hydrogel using Higuchi model d) Model
Fitting of Cytochrome - C Fe@Au Hydrogel using power law model
3.6.4.5 Cytochrome - C Fe@Au PEG
For release of Fe@Au PEG from the cyt c similar models as with other systems was used
to estimate the release kinetics as illustrated in the Figure. From Figure 3.25 it can be
inferred that first order provide superior linear fit compared to zero order model with
rate constant k= 0.0573 hour−1.
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Figure 3.25: a) Model Fitting of Cytochrome - C Fe@Au PEG using zero order
model b) Model Fitting of Cytochrome - C Fe@Au PEG using first order model c)
Model Fitting of Cytochrome - C Fe@Au PEG using Higuchi model d) Model Fitting
of Cytochrome - C Fe@Au PEG using power law model
3.6.4.6 Cytochrome - C Fe@Au PEG Hydrogel
Four models which are used to estimate the release kinetics of drug for the systems
explained above are also used for this system as shown in the Figure 3.26. Higuchi
model is best suited as it provides the best fit for the release kinetics of cyt c from
Fe@Au PEG Hydrogel with rate constant k = 0.127 hour−1/2.
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Figure 3.26: a) Model Fitting of Cytochrome - C Fe@Au PEG Hydrogel using zero
order model b) Model Fitting of Cytochrome - C Fe@Au PEG Hydrogel using first
order model c) Model Fitting of Cytochrome - C Fe@Au PEG Hydrogel using Higuchi
model d) Model Fitting of Cytochrome - C Fe@Au PEG Hydrogel using power law
model
Table 3.1 gives the values of diffusion exponent n the peppas equation for Fe@Au Hydrogel,
Fe@Au PEG and Fe@Au PEG Hydrogel loaded with L-dopa and cyt c.
Table 3.1: Diffusion exponent n of the peppas equation and drug release mechanism
from polymeric systems
Samples n (Diffusion exponent) Geometries Drug release mechanism
L-Dopa drug
Fe@Au Hydrogel 0.92 Thin film Anomalous transport
Fe@Au PEG 1 Thin film Case-II transport
Fe@Au PEG Hydrogel 1 Thin film Case-II transport
Cytochrome c drug
Fe@Au Hydrogel 0.85 Thin film, Cylinder, Sphere Anomalous transport, Case-11 transport
Fe@Au PEG 0.83 Thin film, Cylinder, Sphere Anomalous transport
Fe@Au PEG Hydrogel 0.68 Thin film, Cylinder, Sphere Anomalous transport
Estimated value of n is 0.92 for release of L-dopa from Fe@Au Hydrogel which means
that system’s geometry is thin film and it follows anomalous transport mechanism which
is intermediate between Fickian and case-II transport as discussed in the section. Value
of n for drug release (L-dopa) from Fe@Au PEG and Fe@Au PEG Hydrogel is equal to 1
which indicates that drug release mechanism is based on the case-II transport mechanism
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from a thin film type geometry. It can be stated that drug release from Fe@Au PEG is
based on viscoelastic relaxation-controlled mechanism.
In case of cyt c release from Fe@Au Hydrogel value of diffusion exponent is equal to 0.85,
which means that this system can follow both anomalous and case-II transport mecha-
nism and diffusion exponent value indicates that system can act as thin film, cylinder and
sphere. Similarly, cyt c release from Fe@Au PEG and Fe@Au PEG Hydrogel systems
can also behave like thin film, cylinder and sphere with diffusion exponent values 0.83
and 0.68 respectively. Drug release mechanism from these systems is anomalous trans-
port that is in between Fickian and case-II transport (viscoelastic relaxation-controlled
mechanism).
Table 3.2: Release kinetics and maximum release from the drug loaded systems
Sample Drug) Maximum Release Model t1/2 (hour))
Fe@Au Hydrogel L-dopa 87.20 Zero order 15.60
Fe@Au PEG L-dopa 55.93 Ist order 19.2
Fe@Au PEG Hydrogel L-dopa 28.98 Ist order 12.0
Fe@Au Hydrogel Cytochrome C 55.40 Zero order 21.6
Fe@Au PEG Cytochrome C 89.10 Ist order 12.1
Fe@Au PEG Hydrogel Cytochrome C 50.80 Higuchi 15.4
From table 3.2, it can be concluded that in case of L-dopa, highest release of 87.20 % was
obtained from Fe@Au Hydrogel system, whereas fastest release rate (which is calculated
based on time required for 50 % cumulative drug release, t1/2,, using rate constant
values k for all the systems) was shown by Fe@Au PEG Hydrogel. For the Cytochrome
C, both highest and fastest release were shown by Fe@Au PEG. However, Fe@Au PEG
Hydrogel system also shows similar t1/2, when compared to Fe@Au PEG. These results
support the collapse hypothesis suggested in the work- hydrogels undergo volumetric
collapse with increase in temperature and decrease in pH, however, the Fe@Au NPs
act as bridge molecules pulling together the gelling units. Further differences in both
release rates and percentages can be linked to the interactions of the drug with the
hydrogels- Cytochrome C has stronger interactions with the hydrogel units rather than
with PEG. This leads to faster release in case of Fe@Au PEG compared to the other
systems, for Cytochrome C. On the other hand, the release rate of L Dopa from Fe@Au
PEG Hydrogel is faster as compared to the release rate of Cytochrome C. This can
be attributed to stronger interaction of Cytochrome C than L Dopa with the hydrogel
units. The data further conform to the fact that both the drugs show a faster release
kinetics from Fe@Au PEG Hydrogel than Fe@Au Hydrogel, thereby promoting the need
of combination of PEG and hydrogels with the inorganic NPs in one system.
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Chapter 4
Conclusion
In this thesis, inorganic and polymeric NPs have been combined to form a single nano
drug carrier. This unique system is being studied to exploit the properties such as
magnetic, optical, stimuli responsive behavior and biocompatibility, stemming from both
the components.
Firstly, Fe@Au NPs were synthesized and their physico-chemical properties mapped us-
ing DLS, zeta potential measurements, UV-vis and S(T)EM. Monodisperse population of
Fe@Au NPs was obtained having an average DLS size of 54.30± 0.52 nm and zeta poten-
tial of -36.8±0.9mV with a characteristic LSPR peak at 524 nm. These NPs were stable
in aqeous solution. Afterwards, these inorganic NPs were coated with pNIPAm/AAc
based hydrogels, PEG and a combination of the two in order to exploit properties of
both the Fe@Au NPs and polymeric NPs. These coated samples were also characterized
using the same techniques mentioned above.
Coating was done using two methods, one in which solutions of hydrogel and Fe@Au
NPs were mixed together (Method 1). While in the other method, dry hydrogel in solid
form was added to the Fe@Au NPs solution (Method 2). Although both the meth-
ods showed similar properties (size, zeta potential, UV-vis) of the coated Fe@Au NPs,
Method 2 provides better loading efficiencies. Due to this, Method 2 was used for all
the experiments in this work. pNIMAm/AAc based hydrogels showed a decrease in size
at high temperature due to an entropy driven expulsion of arranged water, when the
hydrogels transit from a hydrophilic to a hydrophobic state above VPTT. The VPTT for
both heating and cooling for the hydrogel is calculated to be 38oC, indicating reversibil-
ity. On the other hand, after coating of Fe@Au NPs with the hydrogels, an increase
in size with increasing temperature was observed. This is hypothesized as cross-linking
effect provided by Fe@Au NPs which brings together the gelling units at higher tem-
perature.ST(E)M data also support this observation. Additionally, a shift in the VPTT
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is observed when compared to only hydrogel, for both heating (39.8oC) and cooling
(39.5oC), without significant compromise in hysteresis. As expected, Fe@Au PEG did
not show appreciable temperature induced effects due to absence hydrogel in this system.
However, Fe@Au PEG Hydrogel system shows appreciable reversibility with VPPT val-
ues for heating and cooling reported as 37.1 oC and 36.7 oC respectively. Effect of pH
on size were also studied for all the system. These results indicates similar outcomes as
depicted by temperature effect, in the sense that decrease in size for hydrogels occur at
low pH, and increase in size occure in case of Fe@Au coated with the polymers at low
pH most probably owing to protonation effect.
Three different drugs were used in these studies for the loading of Fe@Au PEG Hydrogel,
Fe@Au PEG and Fe@Au PEG Hydrogel systems. Drugs used in this study in order of
their decreasing solubilities were Cytochrome C, L-dopa and Coumarin. Loading studies
were optimized with different NP and drug concentrations. Highest loading efficiencies
for Fe@Au PEG Hydrogel, Fe@Au PEG and Fe@Au PEG Hydrogel loaded with L-dopa
were reported as 10.20 %, 8.57 % and 8.00 % respectively. In case of Coumarin, maximum
loading of 8.25 %, 12.02 % and 12.10 % were obtained for Fe@Au Hydrogel, Fe@Au PEG
and Fe@Au PEG Hydrogel respectively. Cytochrome C loading results depict high load-
ing efficiencies of 31.66 % and 32.57 % for Fe@Au Hydrogel and Fe@Au PEG Hydrogel
respectively, whereas, for Fe@Au PEG maximum loading efficiency of 6.76 % was achieved.
The different loading efficiencies can be interpreted in terms of different interactions be-
tween the drug and the carrier.
Release studies at high temperature (40 oC) and low pH (3.5) for the three systems from
the drugs mentioned above, were performed after loading. In case of L-dopa, highest re-
lease of 87.20 % was acquired from Fe@Au Hydrogel system, while Fe@Au PEG Hydrogel
system shows fastest release rate. In case of Cytochrome C, both highest and fastest
release were given by Fe@Au PEG. However, Fe@Au PEG Hydrogel system also shows
almost identical t1/2 in comparison to Fe@Au PEG. These outcomes support the collapse
hypothesis proposed in this research- hydrogels undergoes volumetric collapse at higher
temperature and lower pH, however, the Fe@Au NPs act as bridge molecules pulling
together the gelling units. Further differences in both release rates and percentages can
be linked to the interactions of the drug with the hydrogels. Cytochrome C has stronger
interactions with the hydrogel units rather than with PEG. This leads to faster release
in case of Fe@Au PEG compared to the other systems, for Cytochrome C. In contrast,
the release rate of L Dopa from Fe@Au PEG Hydrogel is faster as compared to the re-
lease rate of Cytochrome C. This can be ascribed to stronger interaction of Cytochrome
C with the hydrogel units than L Dopa. The results further indicates that both the
drugs show a faster release kinetics from Fe@Au PEG Hydrogel than Fe@Au Hydrogel,
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thereby boost the need of combination of PEG and hydrogels with the inorganic NPs in
single system.
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Chapter 5
Future Work
Coumarin showed reasonable loading for all three systems used in this study, but due to
its hydrophobic nature, it shows unstable release kinetics under the conditions employed.
In future it would be quite interesting to use some other techniques to estimate the release
kinetics for this system. It might be possible that under the conditions which were utlized
in this study, Coumarin release is not being effected. Therefore, it is suggested that the
loading study of Coumarin be done at higher temperature, while its release be performed
at normal or lower temperature.
One more suggestion which might provide interesting results is to study the release of
drug from Fe@Au coated NPs at normal temperature, because results observed in this
study indicate that there was decrease in size of coated NPs at 25 oC, and these systems
are almost attaining the same size after heating and cooling cycles at 25 oC and 50 oC.
Furthermore, the coating of Fe@Au NPs with a cationic and anionic polymer separately
can be done. The idea is to coat Fe@Au NPs with anionic polymer and then load this
system with drug 1. Separately, coating of cationic polymer on the Fe@Au NPs can be
done followed by subsequent loading of this system with drug 2. Difference in loading
and release kinetics from these systems can provide further insights for the application
of these nanocarriers in drug delivery. Also, High Performance Liquid Chromatography
(HPLC) technique can be utilized to estimate the loading and release of two drugs on a
single nanocarrier. For example, the system which is suggested above can be modified
by mixing drug 1 loaded on Fe@Au NPs coated with anionic polymer and drug 2 loaded
on Fe@Au NPs coated with cationic polymer. After mixing these systems, their loading
and release studies can be performed with HPLC column.
Future work can also be based on loading of the drug by adding drug during the coating
stage to Fe@Au and polymer solution. This experimental design might provide higher
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loading of drugs on these systems. Release of the drug from this system can be compared
with the drug release study in this work.
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Appendix A
Fe@Au Synthesis
A.1 Calculation for Fe@Au Synthesis
10 mM sodium citrate
(
10×10−3moles
1000ml × 100ml
)
× 294 = 294mg
Here 294 is the molecular weight of sodium citrate
1.5mM chloroauric acid
= 1.5× 10−3mole× 393.8g = 0.5907g0.5907× 10g
0.5907
1000 × 10g = 5.9mgofchloroauricacid
Here 393.8 g is the molecular weight chloroauric acid Dilution of Fe@Au solution
Concentration of Fe@Au were 32.6 mg/ml it was diluted to 10 mg/ml concentration
To prepare 4 ml solution
Requiredvolume×requiredconcentration = x×concentrationofsolution4ml×10mg/ml =
x× 32.6mg/ml
x = 1.22mlofsolutiondissolvedin2.77mlofmilliQwater
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Appendix B
Calibration curves
B.1 Calibration curve of Coumarin
Figure B.1 shows the calibaration curve for Coumarin.
Figure B.1: Calibration curve of Coumarin
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B.2 Calibration curve of L-dopa
Figure B.2 is showing Calibration curve for L-dopa.
Figure B.2: Calibration curve of L-dopa
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B.3 Calibration curve of Cytochrome-C
Figure B.3 is showing Calibration curve for Cytochrome-C.
Figure B.3: Different Steps in coating
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Appendix C
Loading Efficiencies and
Encapsulation Efficiencies
C.1 Loading Efficiency
Loading efficiencies were calculated by using calibration curve of L-dopa at 281 nm and
absorbance values for different systems as follows,
Concentration =
Abs− y0
a∗
(C.1)
=
0.240− 0.0375
0.0135
(C.2)
Concentration = 15.01 mg/ml
Dilution factor = 15.01× 30 = 450.22 (C.3)
=
450.22
1000
= 0.45 (C.4)
Corrected concentration before loading = 0.45 mg/ml
Concentration After loading = 0.40 mg/ml
Loading efficiency =
Mass of drug loaded
intial mass of drug
× 100 (C.5)
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Loading efficiency =
C0 − C1
C0
× 100 (C.6)
Loading efficiency =
0.450− 0.404
0.450
× 100 = 10.20% (C.7)
Loading efficiencies for Coumarin and Cytochrome C were calculated at 277 nm and 409
nm respectively using the similar procedure as used for L-dopa.
C.2 Encapsulation Efficiency
Encapsulation efficiency is calculated by using this formula
Encapsulationefficiency =
Mass of Drug loaded
Mass of NPs
(C.8)
NP concentration = 5 mg/ml Drug concentration = 0.5 mg/ml
Encapsulation efficiency =
10.22
100
× 5
0.50
= 0.01mg/mg (C.9)
0.01× 1000 = 10.20µg/ml
C.3 Loading and Encapsulation efficiencies for different
NPs and drug concentrations-L-dopa
Table C.1: Loading and Encapsulation efficiencies for different NPs and drug
concentrations-L-dopa
NPs concentration (mg/ml) n Drug concentration (mg/ml) Loading Efficiency (%) Encapsulation Efficiency (µg/mg)
Fe@Au Hydrogel L-dopa
5 0.50 10.20 10.02
2.50 0.50 7.95 15.90
5.00 3 1.58 9.48
2.50 3 4.33 51.96
Fe@Au PEG
5 0.50 8.73 9.73
2.50 0.50 2.70 5.40
5 3 5.95 35.70
2.50 3 8.57 102.84
Fe@Au PEG Hydrogel
5 0.50 2.16 2.16
2.50 0.50 5.30 10.60
5 3 7.74 46.44
2.50 3 6.08 72.96
3.75 0.50 2.14 2.85
3.75 3 8 64
10 3 5.77 17.31
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C.4 Loading and Encapsulation efficiencies for different
NPs and drug concentrations-Cytochrom C
Table C.2: Loading and Encapsulation efficiencies for different NPs and drug
concentrations-Cytochrom C
NPs concentration (mg/ml) n Drug concentration (mg/ml) Loading Efficiency (%) Encapsulation Efficiency (µg/mg)
Fe@Au Hydrogel Cytochrome c
5 0.10 31.66 6.33
5 0.50 13.94 13.94
Fe@Au PEG
2.50 0.10 4.41 1.76
2.50 0.50 6.76 13.52
Fe@Au PEG Hydrogel
3.75 0.10 32.57 8.69
3.75 0.50 12.52 16.69
C.5 Loading and Encapsulation efficiencies for different
NPs and drug concentrations-Coumarin
Table C.3: Loading and Encapsulation efficiencies for different NPs and drug
concentrations-Coumarin
NPs concentration (mg/ml) n Drug concentration (mg/ml) Loading Efficiency (%) Encapsulation Efficiency (µg/mg)
Fe@Au Hydrogel Coumarine
5 0.02 8.25 0.33
Fe@Au PEG
2.50 0.10 12.02 4.81
Fe@Au PEG Hydrogel
3.75 0.10 12.10 3.23
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Appendix D
(%) Release and Model Fitting
D.1 (%) Release
(%) Release is calculated as follows,
(%) Release =
(
Asorbance at time t initial - Absrobance at time t final
Absorbance at time t initial
)
×100 (D.1)
(%) Release =
(
0.187 - 0.132
0.187
)
× 100 = 29.3 (D.2)
D.2 Mass Released (mg)
Mass release mg at time t = 2.65 is calculated by using equation below,
Mass Released(mg) = (%Release)×(% Loading efficiency)×
(
Drug concentration (mg/ml)
100
)
(D.3)
(
(29.3)× (31.66)× ( 0.1100))
100
= 0.009 (D.4)
Mt is the cumulative drug release calculated at t = 2.65 by adding all the values of drug
release up to this time point. For this case it is calculated by adding mass release at t0
and t1 and t2.
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Mt = 0 + 0.90 + 0.93 = 1.82 (D.5)
cumulative fraction of drug release at t = 2.65 is calculated by using following equation
F =
Mt
M∞
F =
1.82
19.85
(D.6)
In this equation Mt is mass release at time = 2.65 while M∞ is the mass of drug released
at final time which in this case is t = 43.42.
D.3 Release modelling calculation
L-dopa Fe@Au Hydrogel
Table D.1: L-dopa Fe@Au Hydrogel
t % Release Mass released (mg) Mt (mg) F ln(1-F) t0.5 ln(F) ln(t)
0.00 0.0 0.000 0.000 0.000 0 0
2.05 37.2 0.019 0.019 0.085 -0.089 1.4329 -2.463 0.7195
6.09 44.5 0.023 0.042 0.187 -0.207 2.4671 -1.676 1.8061
12.07 67.1 0.034 0.076 0.341 -0.417 3.4742 -1.077 2.4907
14.14 65.6 0.033 0.109 0.491 -0.675 3.7599 -0.711 2.6488
19.15 59.5 0.030 0.140 0.627 -0.987 4.3765 -0.467 2.9525
23.75 75.6 0.039 0.178 0.800 -1.611 4.8737 -0.223 3.1677
32.29 87.2 0.044 0.223 1.000 5.6821 0 3.4747
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L-dopa Fe@Au PEG
Table D.2: L-dopa Fe@Au PEG
t % Release Mass released (mg) Mt (mg) F ln(1-F) t0.5 ln(F) ln(t)
0.00 0.0 0.000 0.000 0.000 0 0
2.18 9.0 2.309 2.309 0.030 -0.03 1.4776 -3.506 0.7809
4.03 6.3 1.612 3.921 0.051 -0.052 2.0083 -2.977 1.3946
6.13 17.9 4.595 8.515 0.111 -0.117 2.4766 -2.201 1.8137
8.15 17.7 4.551 13.067 0.170 -0.186 2.8548 -1.773 2.098
10.18 19.4 4.999 18.065 0.235 -0.268 3.1911 -1.449 2.3208
12.23 17.3 4.460 22.525 0.293 -0.346 3.4976 -1.229 2.5042
14.27 22.9 5.879 28.404 0.369 -0.461 3.7771 -0.997 2.6579
16.33 13.2 3.392 31.796 0.413 -0.533 4.0415 -0.884 2.7932
18.43 24.6 6.317 38.113 0.495 -0.684 4.2934 -0.703 2.9142
20.47 18.9 4.849 42.962 0.558 -0.817 4.524 -0.583 3.0188
24.48 24.0 6.158 49.120 0.638 -1.017 4.9481 -0.449 3.198
27.93 14.7 3.777 52.897 0.687 -1.162 5.2852 -0.375 3.3298
48.58 37.7 9.689 62.586 0.813 -1.678 6.9702 -0.207 3.8833
59.08 55.9 14.380 76.966 1.000 7.6866 0 4.0789
L-dopa Fe@Au PEG Hydrogel
Table D.3: L-dopa Fe@Au PEG Hydrogel
t % Release Mass released (mg) Mt (mg) F ln(1-F) t0.5 ln(F) ln(t)
0.00 0.0 0.000 0.000 0.000 0 0
1.08 0.6 0.002 0.002 0.004 -0.004427 1.0408 -5.422 0.08
3.12 9.4 0.022 0.024 0.070 -0.072951 1.7654 -2.654 1.1368
5.12 12.5 0.030 0.054 0.159 -0.172812 2.262 -1.841 1.6325
7.15 5.0 0.012 0.066 0.194 -0.215321 2.6739 -1.641 1.9671
11.22 11.0 0.026 0.092 0.271 -0.316227 3.3491 -1.305 2.4174
13.35 19.4 0.047 0.139 0.408 -0.52378 3.6538 -0.897 2.5915
15.20 16.8 0.040 0.179 0.526 -0.747269 3.8987 -0.642 2.7213
17.25 22.0 0.053 0.232 0.681 -1.142938 4.1533 -0.384 2.8478
24.67 16.3 0.039 0.271 0.796 -1.589513 4.9666 -0.228 3.2055
52.93 29.0 0.070 0.341 1.000 7.2755 0 3.969
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Cytochrome c Fe@Au Hydrogel
Table D.4: Cytochrome c Fe@Au Hydrogel
t % Release Mass released (mg) Mt (mg) F ln(1-F) t0.5 ln(F) ln(t)
0 0 0.000 0.000 0.000 0 0
1.6 28.3 0.009 0.009 0.045 -0.04619 1.2649 -3.098 0.47
2.65 29.3 0.009 0.018 0.092 -0.09636 1.6279 -2.387 0.9746
3.65 31.5 0.010 0.028 0.142 -0.15327 1.9105 -1.951 1.2947
5.63 31.8 0.010 0.038 0.193 -0.21421 2.3728 -1.646 1.7281
7.65 35.4 0.011 0.049 0.249 -0.28673 2.7659 -1.389 2.0347
9.63 37.7 0.012 0.061 0.309 -0.37021 3.1032 -1.173 2.2649
11.93 38 0.012 0.073 0.370 -0.46206 3.454 -0.994 2.4791
15.85 41.9 0.013 0.087 0.437 -0.5742 3.9812 -0.828 2.7632
20.85 40.1 0.013 0.099 0.501 -0.69474 4.5662 -0.692 3.0374
25.47 49.7 0.016 0.115 0.580 -0.86765 5.0468 -0.545 3.2375
29.62 44.7 0.014 0.129 0.651 -1.0537 5.4424 -0.429 3.3884
33.98 54.6 0.017 0.147 0.738 -1.34108 5.8292 -0.303 3.5258
37.1 54 0.017 0.164 0.825 -1.74047 6.091 -0.193 3.6136
39.62 54.6 0.017 0.181 0.912 -2.42637 6.2944 -0.093 3.6793
43.42 55.4 0.018 0.199 1.000 6.5894 0 3.7709
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Cytochrome c Fe@Au PEG
Table D.5: Cytochrome c Fe@Au PEG
t % Release Mass released (mg) Mt F ln(1-F) t0.5 ln(F) ln(t)
0.00 0.00 0.000 0.000 0 0 0.00
0.63 24.88 0.008 0.008 0.0259 -0.0263 0.80 -3.652 -0.457
1.60 45.98 0.016 0.024 0.0739 -0.0768 1.26 -2.605 0.47
2.65 63.15 0.021 0.045 0.1397 -0.1505 1.63 -1.968 0.9746
3.78 45.15 0.015 0.061 0.1868 -0.2068 1.95 -1.678 1.3306
5.75 61.78 0.021 0.081 0.2512 -0.2893 2.40 -1.381 1.7492
7.77 53.70 0.018 0.100 0.3072 -0.367 2.79 -1.18 2.0498
9.75 68.21 0.023 0.123 0.3783 -0.4754 3.12 -0.972 2.2773
12.10 85.95 0.029 0.152 0.468 -0.631 3.48 -0.759 2.4932
16.03 88.61 0.030 0.182 0.5604 -0.8218 4.00 -0.579 2.7747
21.03 73.34 0.025 0.206 0.6368 -1.0129 4.59 -0.451 3.0461
25.65 80.16 0.027 0.234 0.7204 -1.2744 5.06 -0.328 3.2445
29.78 87.75 0.030 0.263 0.8119 -1.6708 5.46 -0.208 3.3939
34.15 91.26 0.031 0.294 0.9071 -2.3757 5.84 -0.098 3.5308
43.40 89.14 0.030 0.324 1 6.59 0 3.7705
Cytochrome c Fe@Au PEG Hydrogel
Please add the following required packages to your document preamble: booktabs graph-
icx
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Table D.6: Cytochrome c Fe@Au PEG Hydrogel
t % Release Mass released (mg) Mt F ln(1-F) t0.5 ln(F) ln(t)
0.00 0.00 0.000 0.000 0 0 0.00
0.55 30.05 0.010 0.010 0.0433 -0.044 0.74 -3.139 -0.598
1.52 29.49 0.010 0.019 0.0858 -0.09 1.23 -2.456 0.4165
2.55 31.04 0.010 0.030 0.1306 -0.14 1.60 -2.036 0.9361
3.53 30.42 0.010 0.039 0.1744 -0.192 1.88 -1.746 1.2622
5.53 36.55 0.012 0.051 0.2271 -0.258 2.35 -1.482 1.7108
7.52 39.19 0.013 0.064 0.2836 -0.333 2.74 -1.26 2.0171
9.45 38.80 0.013 0.077 0.3395 -0.415 3.07 -1.08 2.246
11.67 41.08 0.013 0.090 0.3987 -0.509 3.42 -0.92 2.4567
15.48 43.56 0.014 0.104 0.4615 -0.619 3.93 -0.773 2.7398
20.50 45.28 0.015 0.119 0.5268 -0.748 4.53 -0.641 3.0204
25.10 43.57 0.014 0.133 0.5896 -0.891 5.01 -0.528 3.2229
29.17 44.23 0.014 0.148 0.6533 -1.059 5.40 -0.426 3.373
33.72 49.02 0.016 0.164 0.724 -1.287 5.81 -0.323 3.518
36.53 47.21 0.015 0.179 0.792 -1.57 6.04 -0.233 3.5982
38.97 44.8790637 0.015 0.194 0.8567 -1.943 6.24 -0.155 3.6627
42.77 48.5825748 0.016 0.209 0.9267 -2.614 6.54 -0.076 3.7558
47.73 50.8296489 0.017 0.226 1 6.91 0 3.8656
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VPTT Calculations
E.1 Procedure used to calculate VPTT
Developed approach, which was used to evaluate collapse temperature involves plotting
a spectroscopic parameter along with temperature. The following plot E.1 represents
the variation of Optical Density along with Absolute Temperature;
Figure E.1: variation of Optical Density along with Absolute Temperature
The experimental parameter taken into account for our studies is ‘Alpha’, which is
defined as,
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α =
(
DH
D0
)3
(E.1)
Hydrogel is a mixture of moieties with different sizes. As a result of which, the hydrogel
doesn’t have a distinctive value of collapse temperature, but varies over a range. Alpha
is plotted against temperature. At any point on the curve, the hydrogel exists in a par-
tially collapsed state. Therefore, we can assume that at the mean collapse temperature,
denoted by (Tm), of the complete hydrogel, the collapsed state lies in equilibrium with
the swelled state. The swelled state area lies to the left of Tm on the swelling curve,
whereas the collapsed state area lies to the right of Tm.
The program tries to find out the probable value of collapse temperature by equating
the swelling and the collapsed state areas. Therefore, at the ideal situation, both these
areas should be equal. The area is calculated by integrating the curve and the method
applied here is the “Simpson’s 1/3rd Rule” which calculates the area under the curve
by integrating the function as follows,
Figure E.2: Equation used to estimate area under the curve
For the first part of the curve, measured from the lower temperature (Ta), the system
integrates between the limits Ta to Tm. Similarly, for the next part of the curve, the
limits vary from Tm to the higher temperature limit, i.e. (Tb). SigmaPlotTM version
12.5 is used as a tool to plot the data points and obtain a smooth curve fit using the
Equation Category – ‘Sigmoidal’ and in it the Equation Name – ‘Sigmoid, 5 Parameter’.
The fit, shown by equation below, provides the user the value of 5 parameters which the
user needs to input into the MATLAB code.
Figure E.3: ‘Sigmoid, 5 Parameter’ equation
The user then runs the code and enters these parameters along with the value of rel-
ative tolerance as well as the number of iterations desired by the user. The program
calculates the collapse temperature by calculating the relative difference in the areas of
the collapsed as well as the swelled state up to the input tolerance value. The program,
automatically adjusts the value of the number of iterations, if the desired tolerance is
not reached within the iterations provided by the user. At the end of the program run,
it also generates the curve, thereby confirming with the SigmaPlotTM curve about the
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dependency as well as the reliability of the MATLABTM code. The point, marked with
a red circle on the curve, depicts the collapse temperature of the entire system. It is to
be noted that the user is free to enter the temperature in the absolute, as well as the
Celsius scale. The program can be used to study both, the heating as well as the cooling
curves.
The choice of the tolerance and the number of iterations has been left with the user. A
higher degree of precision has been observed by choosing a lower value of tolerance or
a higher number of iterations. For this particular study case, the value of tolerance has
been set to 0.001 and collapse temperature has been calculated by changing the number
of iterations. A mean value of all these collapse temperatures is then selected as the
overall collapse temperature of the system (separately for heating and cooling).
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UV-vis and DLS Plots
F.1 UV-vis spectra for step wise coating of Hydrogel on
Fe@Au
This Figure F.1 is showing UV-vis spectra for step wise coating of Hydrogel on Fe@Au.
Figure F.1: UV-vis spectra for step wise coating of Hydrogel on Fe@Au
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F.2 UV-vis spectra of Fe@Au, Hydrogel, Fe@Au Hydrogel
M1 and M2
UV-vis spectra for effect of coating of Hydrogel with method 1 and method 2 is shown
in the Figure F.2,
Figure F.2: UV-vis spectra of Fe@Au, Hydrogel, Fe@Au Hydrogel M1 and M2
F.3 UV-vis spectra of Fe@Au, Fe@Au Hydrogel M1 and
M2
Figure F.3 UV-vis spectra of Fe@Au and coating of Fe@Au by method 1 and 2.
Figure F.3: UV-vis spectra of Fe@Au, Fe@Au Hydrogel M1 and M2
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F.4 Reversibility of Fe@Au Hydrogel M1
Reversibility of Fe@Au Hydrogel caoted by method 1 at a heating rate of 10 C is shown
in the Figure F.4
Figure F.4: Reversibility of Fe@Au Hydrogel M1 at a heating rate of 10 C
F.5 Reversibility of Fe@Au Hydrogel M2
Reversibility of Fe@Au Hydrogel caoted by method 1 at a heating rate of 10 C is F.5.
Figure F.5: Reversibility of Fe@Au Hydrogel M1 at a heating rate of 10 C
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Appendix F. UV-vis and DLS Plots
F.6 Variation in size at different hydrogel concentrations
The Figure F.6 is showing Variation of Size with the concentration of hydrogel
Figure F.6: Variation in size at different hydrogel concentrations
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Appendix F. UV-vis and DLS Plots
F.7 Cyclic measurements of Hydrogel at 25 oC and 40 oC
The Figure F.6 is showing cyclic size measurements for hydrogel at 25 oC and 40 oC
Figure F.7: Cyclic measurements of Hydrogel at 25 oC and 40 oC
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Appendix G
Choice of drug concentrations
G.1 Coumarin
Coumarin Drug concentration
L-Dopa minimum concentration used = 0.50 mg/ml L-Dopa maximum concentration
used = 3.00 mg/ml L-Dopa solubility = 3.20 mg/ml coumarine solubility (y) = 0.10
mg/ml
x for 0,5 mg/ml drug concentration = 0.503.20 × 100 = 15.63
x (%) of y = 15.63100 × 0.10 = 0.015625
x for 3 mg/ml drug concentration = 33.20 × 100 = 93.75
x (%) of y = 93.75100 × 0.10 = 0.09375
Coumarin Drug concentration used
= 0.02 mg/ml and 0.1 mg/ml
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